

TNF U-Ö

Ubriani R, Van Voorhees AS

Onset of Psoriasis During Treatment With TNF- α Antagonists: A Report of 3 Cases

Arch Dermatol. 2007;143:270-2. Otettu M 21.11.09 Ei oteta

[EXTRACT](#) | [FULL TEXT](#)

Ueno Y, Shimamoto M, Miyanaka Y, et al.

Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B.

Dig Dis Sci 2005; 50:163–6. Otettu M 21.11.09 OK

[\[CrossRef\]](#)[\[ISI\]](#)[\[Medline\]](#)

Ulfgren AK, Andersson U, Engstrom M et al

Systemic anti-tumor necrosis factor therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor synthesis.

Arthritis Rheum 2000; 43: 2391-6.

Kokotekstinä OK*

[Etanercept is safely used for treating psoriatic arthritis in a patient complicated with type 1 hereditary angioedema.](#)

Umegaki N, Kira M, Horiuchi T, Itoi S, Tani M, Yokomi A, Tanemura A, Miyahara H, Hatanaka M, Kitamura H, Kitano E, Katayama I.

Mod Rheumatol. 2012 Feb 5. [Epub ahead of print]

PMID:

22310967 Otettu 7.9.2012 [OK](#)

[PubMed - as supplied by publisher]

[Related citations](#)

[Improvement of rheumatoid arthritis and autoimmune hepatitis in a patient treated with the tumor necrosis factor inhibitor, etanercept.](#)

Umekita K, Miyauchi S, Ueno S, Takajo I, Kusumoto K, Hasuike S, Umekita Y, Tanaka H, Nagata K, Nagatomo Y, Kataoka H, Shimoda K, Okayama A.

Intern Med. 2011;50(11):1245-9. Epub 2011 Jun 1. [Kokotekstinä](#) [Ei oteta](#)

PMID:

21628943

[PubMed - indexed for MEDLINE]

[Free Article](#)

[Related citations](#)

[Use of anti-tumor necrosis factor biologics in the treatment of rheumatoid arthritis does not change human T-lymphotropic virus type 1 markers: a case series.](#)

Umekita K, Umeki K, Miyauchi S, Ueno S, Kubo K, Kusumoto N, Takajo I, Nagatomo Y, Okayama A.

Mod Rheumatol. 2013 Nov 4. [Epub ahead of print]

PMID:

24252020

[PubMed - as supplied by publisher] ei ole M

[Related citations](#)

277.

Risk of herpes zoster in psoriatic patients undergoing biologic treatment.

Umezawa Y, Fukuchi O, Ito T, Saeki H, Nakagawa H.

J Dermatol. 2014 Feb;41(2):168-70. doi: 10.1111/1346-8138.12370. Epub 2014 Jan 16.

PMID:

24433215

[PubMed - in process] Otettu 18.6.18

Related citations

Drug survival rates in patients with psoriasis after treatment with biologics.

Umezawa Y, Nobeyama Y, Hayashi M, Fukuchi O, Ito T, Saeki H, Nakagawa H.

J Dermatol. 2013 Dec;40(12):1008-13. doi: 10.1111/1346-8138.12353. Epub 2013 Dec 4.

PMID:

24304288

[PubMed - in process] Otettu 18.6.18

[Related citations](#)

13.

[Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The Poetic Study.](#)

Ungar B, Engel T, Yablecovitch D, Lahat A, Lang A, Avidan B, Har-Noy O, Carter D, Levhar N, Selinger L, Neuman S, Natour OH, Yavzori M, Fudim E, Picard O, Kopylov U, Chowers Y, Naftali T, Broide E, Shachar E, Eliakim R, Ben-Horin S.

Am J Gastroenterol. 2018 Jun 5. doi: 10.1038/s41395-018-0073-0. [Epub ahead of print]

PMID:

29867175 Otettu 18.6.18

[Similar articles](#)

United States Food and Drug Administration. Tumor necrosis factor alpha (TNF-a) antagonists [infliximab (marketed as REMICADE), etanercept (marketed as ENBREL), and adalimumab (marketed as HUMIRA)]: serious skin reactions. FDA Drug Saf Newslett 2008;1:

18 -22. ei ole M

[Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists.](#)

Urbano PC, Socco VT, Azevedo VF.

Biologics. 2014 Jul 31;8:211-20. doi:

10.2147/BTT.S57253. eCollection 2014. Review.

PMID:

25114503

[PubMed] Otettu 28.10.16

[Free PMC Article](#)

[Related citations](#)

[CD4+ T-cells lymphocytosis and reduction of neutrophils during treatment with adalimumab: Challenge and dechallenge study.](#)

Ursini F, Naty S, Bruno C, Calabria M,

Spagnolo F, Grembiale RD.

Clin Immunol. 2010 Jun;135(3):499-500. Epub 2010 Mar 12. No abstract available. **Ei oteta**

Otettu 13.10.12

MPMID: 20219434 [PubMed - indexed for MEDLINE][Related citations](#)

[[Etanercept: does it constitute a risk factor for development of cerebral venous thrombosis?](#)].

Usero-Ruiz M, Díaz-Sánchez M, Moniche-Álvarez F.

Rev Neurol. 2014 Mar 1;58(5):239-40. Spanish.

PMID:

24570365

[PubMed - in process] **ei oteta**

[Free Article](#)

Related citations

US Food and Drug Administration. Safety Update on TNF-alpha Antagonists: Infliximab and Etanercept. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3779b2_01_cber_safety%20_revision2.pdf (accessed 10 February 2003). **Ei oteta**

Usmani N, Clayton TH, Everett S, Goodfield MD.
Variable response of hidradenitis suppurativa to infliximab in four patients.

Clin Exp Dermatol 2007;32:204-5. **Otettu 7.9.2012 Ei oteta**

Uthman I, Husari A, Touma Z, Kanj SS.
Fatal streptococcal toxic shock
syndrome in a patient with rheumatoid arthritis treated with etanercept.
Rheumatology (Oxford) 2005;44:1200-1. **Kokotekstinä**
Ei oteta

[Utz JP](#), Limper AH, Kalra S,ym.

Etanercept for the Treatment of Stage II and III Progressive Pulmonary Sarcoidosis.
Chest 2003;124:177-85. [Kokotekstinä](#) OK *

[Multiple sclerosis during adalimumab treatment in a case with ankylosing spondylitis.](#)

Uygunoğlu U, Uluduz D, Taşçılar K, Saip S.

Rheumatol Int. 2012 Dec 27. [Epub ahead of print]

PMID:

23269571

[PubMed - as supplied by publisher] Otettu 18.6.18

[Related citations](#)

[Clinical and radiographic results from a 2-year comparison of once-weekly versus twice-weekly administration of etanercept in biologics-naïve patients with rheumatoid arthritis.](#)

Wada T, Son Y, Ozaki Y, Nomura S, Iida H.

Mod Rheumatol. 2012 Feb 3. [Epub ahead of print]

PMID:

22302136 **Otettu 7.9.2012 Ei oteta**

[PubMed - as supplied by publisher]

[Related citations](#)

Isolated Bilateral Gastrocnemius Myositis in Crohn Disease Successfully Treated with Adalimumab.

Vadala di Prampero S, Marino M, Toso F, Avellini C, Nguyen V, Sorrentino D.

Case Rep Gastroenterol. 2016 Nov 7;10(3):661-667. eCollection 2016 Sep-Dec.

PMID:

27920658 Ota kotona

[Free PMC Article](#)

[Similar articles](#)

Establishment of the first WHO International Standard for etanercept, a TNF receptor II Fc fusion protein: Report of an international collaborative study.

Wadhwa M, Bird C, Dilger P, Rigsby P, Jia H, Gross MEB; participants of the study.

J Immunol Methods. 2017 Aug;447:14-22. doi: 10.1016/j.jim.2017.03.007. Epub 2017 Mar 10.

PMID:

28288790 Ota kotona

[Free Article](#)

[Similar articles](#)

WAETZIG, G.H. & S. SCHREIBER. 2004. Mechanisms of infliximab: the reverse side

of a drug effect. Inflamm. Bowel Dis. 10(Suppl 1): S38–43. **ei oteta**

Effect of TNF- α inhibitors on transcriptional levels of pro-inflammatory interleukin-33 and Toll-like receptors-2 and -9 in psoriatic plaques.

Vageli DP, Exarchou A, Zafiriou E, Doukas PG,
Doukas S, Roussaki-Schulze A.

Exp Ther Med. 2015 Oct;10(4):1573-1577.

PMID:

26622528 Otettu 28.10.16

Free PMC Article

Similar articles

Wagner TE, Huseby ES, Huseby JS.

Exacerbation of mycobacterium tuberculosis enteritis masquerading as crohn's disease after treatment with a tumor necrosis factor- inhibitor.

Am J Med 2002;112:67-9. **Otettu 7.9.2012 OK**

Wagner U, Pierer M, Kaltenhauser S et al
Clonally expanded CD4+CD28null T cells in rheumatoid arthritis use distinct combinations of T cell receptor BV and BJ elements.
Eur J Immunol 2003; 33: 79-84. [ei oteta](#)
[Links](#)

Wailoo A, Bansback N, Chilcott J
Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance
Rheumatology 2008; 47: 119 - 20. [Ei oteta](#)
[Kokotekstinä](#)

[Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab.](#)

Wagner C, Visvanathan S, Braun J, van der Heijde D, Deodhar A, Hsu B, Mack M, Elashoff M, Inman RD.
Ann Rheum Dis. 2012 May;71(5):674-80. Epub 2011 Oct 28. [Kokotekstinä](#) [Ei oteta](#)
PMID:

22039165

[PubMed - indexed for MEDLINE]

[Free PMC Article](#)

[Related citations](#)

Wajdula J, Sridharan S, Fletcher T, MacPeek D, Meier E. Rates of IBD in patients receiving etanercept and placebo in AS. Arthritis Rheum 2007;56:S256-7. [ei oteta](#)

[Repeat etanercept administration restores clinical response of patients with rheumatoid arthritis.](#)

Wakabayashi H, Sudo A, Nishioka Y, Hasegawa M, Minami Y, Nishioka K.

Rheumatol Int. 2011 Sep 7. [Epub ahead of print] Otettu 13.10.12 [Ei oteta](#)

PMID:

21898060

[PubMed - as supplied by publisher]

[Related citations](#)

Wakefield RJ, Freeston JE, Hensor EM, Bryer D, Quinn MA, Emery P. Delay in imaging versus clinical response: a rationale for prolonged treatment with anti-tumor necrosis factor medication in early rheumatoid arthritis. Arthritis Rheum 2007;57:1564 – 67.

Otettu 7.9.2012 [Ei oteta](#)

Valesini G, Iannuccelli C, Marocchi E, Pascoli L, Scalzi V, Di Franco M.

Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev 2007;7:35–41.

Otettu 7.9.2012 [Ei oteta](#)

Walker RE, Spooner KM, Kelly G, McCloskey RV, Woody JN, Falloon J, Baseler M, Piscitelli SC, Davey RT Jr, Polis MA, Kovacs JA, Masur H, and Lane HC: Inhibition of immunoreactive tumor necrosis factor-a by a chimeric antibody in patients infected with human immunodeficiency virus type 1. *J Infect Dis* 1996;174:63-68. **Otettu 7.9.2012 Ei oteta**

Walker UA, Tyndall A, Daikeler T
Rheumatic conditions in human immunodeficiency virus infection
Rheumatology 2008; 47: 952 - 9. **Otettu 7.9.2012 Ei oteta**
[\[Abstract\]](#) [\[Full Text\]](#) [\[PDF\]](#)

Wallace DJ.
The use of etanercept and other tumor necrosis factor-alpha blockers in infertility: it's time to get serious.
J Rheumatol 2003;30:1897e9. **Ei oteta**
Otettu 7.9.2012

Pityriasis rubra pilaris responding rapidly

[to adalimumab.](#)

Walling HW, Swick BL.

Arch Dermatol. 2009 Jan;145(1):99-101. No abstract available. Otettu 7.9.2012 [Ei oteta](#)
PMID: 191533[PubMed - indexed for MEDLINE][Related citations](#)

Wallis RS, Broder MS, Wong JY et al

Granulomatous infectious diseases associated with tumor necrosis factor antagonists.
Clin Infect Dis 2004; 38: 1261-5. [OK*](#)

[Kokotekstinä](#)

Wallis RS, Kyambadde P, Johnson JL et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004; 18:257-64. Otettu 7.9.2012 [Ei oteta](#)

Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction.

Clin Infect Dis 2004;39:1254—5. Otettu 7.9.2012 [Ei oteta](#)

Wallis RS, Broder M, Wong J, Lee A, Hoq L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 2005;41(Suppl. 3): S194-8. **Otettu 7.9.2012**

Wallis RS, Ehlers S.

Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. **Otettu 7.9.2012**

Semin Arthritis Rheum 2005; 34 Suppl 5: 34-8. Otettu M 21.11.09

[Links](#)

[Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade.](#)

Wallis RS.

Arthritis Rheum. 2008 Apr;58(4):947-52.

PMID: 18383389 [PubMed - indexed for MEDLINE] **Otettu 7.9.2012 Ei oteta**

[Related Articles](#) [Free article at journal site](#)

[Adalimumab treatment of life-threatening tuberculosis.](#)

Wallis RS, van Vuuren C, Potgieter S.

Clin Infect Dis. 2009 May 15;48(10):1429-32. **Otettu 7.9.2012 Ei oteta**

MID: 19364287 [PubMed - indexed for MEDLINE][**Free Article**](#)[Related citations](#)

[Young male patient diagnosed with cutaneous polyarteritis nodosa successfully treated with etanercept.](#)

[Valor L, Monteagudo I, de la Torre I, Fernández CG, Montoro M, Longo JL, Carreño L.](#)

[Mod Rheumatol. 2013 Jan 30. \[Epub ahead of print\]](#)

[PMID:](#)

[23359007](#)

[\[PubMed - as supplied by publisher\]](#) ei oteta

[Related citations](#)

[Effect of Adalimumab on Peripheral Blood Mononuclear Cells in Non-Infectious Uveitis.](#)

[Walscheid K, Weinhage T, Foell D, Heinz C, Kasper M, Heiligenhaus A.](#)

[Ocul Immunol Inflamm. 2017 Oct 11:1-8. doi: 10.1080/09273948.2017.1374415. \[Epub ahead of print\]](#)

[PMID:](#)

[29020495 Ota v, 2019](#)

[Similar articles](#)

Walsh N. TNF Inhibitor Puts the Brakes On Refractory Hidradenitis. Skin & Allergy News 2005;36:22. ei ole M

Walsh CAE, Minnock P, Slattery C et al
Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis
Rheumatology 2007; 46: 1148 - 52. [Kokotekstinä ei oteta](#)

[The impact of disease activity and tumour necrosis factor- \$\alpha\$ inhibitor therapy on cytokine levels in juvenile idiopathic arthritis.](#)

Walters HM, Pan N, Lehman TJ, Adams A, Kalliolias GD, Zhu YS, Santiago F, Nguyen J, Sitaras L, Cunningham-Rundles S, Walsh TJ, Toussi SS.

Clin Exp Immunol. 2016 Jun;184(3):308-17. doi: 10.1111/cei.12782. Epub 2016 Apr 13.

PMID:

26934060 Ota kotona

[Free PMC Article](#)

[Similar articles](#)

[Severe hypoglycemia after initiation of anti-tumor necrosis factor therapy with etanercept in a patient with generalized pustular psoriasis and type 2 diabetes mellitus.](#)

Wambier CG, Foss-Freitas MC, Paschoal RS, Tomazini MV, Simão JC, Foss MC, Foss NT.

J Am Acad Dermatol. 2009 May;60(5):883-5. No abstract available.

Otettu 7.9.2012 Ei oteta

PMID: 19389539 [PubMed - indexed for MEDLINE]

[Related Articles](#)

Van Assche G, Rutgeerts P. Anti-TNF agents in Crohn's disease. *Expert Opin Investig Drugs*. 2000;9:103-111. **ei ole M** [PUBMED](#)

Van Assche G, Magdalaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. *Gastroenterology* 2008; 134: 1861-8.

Otettu 7.9.2012 Ei oteta

[Mucosal healing and anti TNFs in IBD.](#)

van Assche G, Vermeire S, Rutgeerts P.

Curr Drug Targets. 2010 Feb;11(2):227-33. **ei ole M** MID: 20210770
[PubMed - indexed for MEDLINE][Related citations](#)

[Commentary: BMI and the need for adalimumab dose escalation in Crohn's disease.](#)

Van Assche G, Baert F, Vermeire S.

Aliment Pharmacol Ther. 2012 Apr;35(7):848; discussion 849. doi:

10.1111/j.1365-2036.2012.05023.x. No abstract available. **Otettu 7.9.2012 Ei oteta**

PMID:

22404407

[PubMed - indexed for MEDLINE]

[Related citations](#)

[Case series demonstrating improvement in chronic cutaneous sarcoidosis following treatment with TNF inhibitors.](#)

[Wanat KA, Rosenbach M.](#)

[Arch Dermatol. 2012 Sep 1;148\(9\):1097-100. doi: 10.1001/archdermatol.2012.1322. No abstract available.](#)

[PMID:](#)

[22986883](#)

[\[PubMed - indexed for MEDLINE\]](#) Otettu 18.6.18

[Related citations](#)

[Select item 22986848273.](#)

[Intrapatient Variability in the Pharmacokinetics of Etanercept Maintenance Treatment.](#)

[van Bezooijen JS, Schreurs MWJ, Koch BCP, Velthuis HT, van Doorn MBA, Prens EP, van Gelder T.](#)

[Ther Drug Monit. 2017 Aug;39\(4\):333-338. doi: 10.1097/FTD.0000000000000384.](#)

[PMID:](#)

[28691952](#) Otettu 18.6.18

[Similar articles](#)

[Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment.](#)

Van L, Modi SV, Yang DJ, Hsu S.

Arch Dermatol. 2008 Jun;144(6):804-6. No abstract available. **Otettu**

7.9.2012 Ei oteta

PMID: 18559778 [PubMed - indexed for MEDLINE]

[Related Articles](#)

Van Balkom BPJ, Schoon EJ, Stockbrügger RW et al

Effects of anti-tumour necrosis factor- α therapy on the quality of life in Crohn's disease.

Alimentary Pharmacology and Therapeutics 2002; 16:1101-7 Otettu M 21.11.09 **Ei oteta**

[Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring \(DREAM\) registry.](#)

van Dartel SA, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, Hartkamp A, van de Laar MA, van Riel PL.

Ann Rheum Dis. 2012 Aug 11. [Epub ahead of print] **Otettu 18.6.18**

PMID:

22887849

[PubMed - as supplied by publisher]

[Related citations](#)

[Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.](#)

van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L,

Wajdula J.

Br J Dermatol. 2008 Nov;159(5):1177-85. Epub 2008 Jul 31. **Otettu**

7.9.2012 OK

PMID: 18673365 [PubMed - indexed for MEDLINE]

[Related Articles](#)

Vanbiervliet G, Anty R, Schneider S, Arab K, Rampal P, Hebuterne X
Sweet's syndrome and erythema nodosum associated with Crohn's disease
treated by infliximab. Gastroenterol Clin Biol 2002;26:295-7. **ei oteta**
[Medline](#)

[Chronic hepatitis E in a patient with rheumatoid arthritis treated with adalimumab and methotrexate.](#)

van Bijnen ST, Ledebuur M, Martens HA.

Rheumatology (Oxford). 2017 Mar 1;56(3):497-498. doi: 10.1093/rheumatology/kew388. No abstract available.

PMID:

27940593 **Otettu 18.6.18**

[Similar articles](#)

[Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring \(DREAM\) registry.](#)

van Dartel SA, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, Hartkamp A, van de Laar MA, van Riel PL.

Ann Rheum Dis. 2012 Aug 11. [Epub ahead of print]

PMID:

22887849 Otettu 20.10.12 OK

[PubMed - as supplied by publisher]

[Related citations](#)

van den Bemt B J F, den Broeder A A, Snijders G F et al
Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.

Ann Rheum Dis 2008; 67: 1697-701 Otettu M 21.11.09 Ei oteta

- [\[Abstract\]](#) [\[Full Text\]](#)

178.

[Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2.](#)

Van den Bosch F, Mease PJ, Sieper J, Baeten DL, Xia Y, Chen S, Pangan AL, Song IH.

RMD Open. 2018 Feb 26;4(1):e000566. doi: 10.1136/rmdopen-2017-000566. eCollection 2018.

PMID:

29531780 Ota kotona

[Free PMC Article](#)

[Similar articles](#)

Van den Brande JMH, Koehler TC, Zelinkova Z et al
Prediction of antitumour necrosis factor clinical efficacy by real-time
visualisation of apoptosis in patients with Crohn's disease
Gut 2007; 56: 509 - 17. [Kokotekstinä](#) [PDF](#) [Ei oteta](#)

Adalimumab Significantly Reduces the Recurrence Rate of Anterior Uveitis in Patients with Ankylosing Spondylitis.

van Denderen JC, Visman IM, Nurmohamed MT, Suttorp-Schulten MS, van der Horst-Bruinsma IE.

J Rheumatol. 2014 Aug 1. pii: jrheum.131289. [Epub ahead of print]

PMID:

25086071

[PubMed - as supplied by publisher] Otettu 18.6.18

[Related citations](#)

van de Putte L, van Riel P, den Broeder A, et al.
A single dose placebo-controlled phase I study of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis.
Arthritis Rheum 1998;41 (suppl):57. **ei oteta**

Van de Putte LBA, Atkins C, Malaise M, ym.
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.
Ann Rheum Dis 2004;63:508-16. Kokotekstinä **OK***
Sitaatit tarkistettu 6.1.08

Van den Bosch F, Kruithof E, Baeten D et al
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.
Ann Rheum Dis 2000;59:428–33 Kokotekstinä . **OK ***

Van den Bosch F, Kruithof E, De Vos M et al
Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms.
Lancet 2000, 356:1821-2 Otettu M 21.11.09 **OK**
[\[PubMed Abstract\]](#)[\[Publisher Full Text\]](#)

Van den Bosch F, Baeten D, Kruithof E, et al.

Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.

Ann Rheum Dis 2001;60: iii33-36 [Kokotekstinä](#) OK *

Van den Bosch F, Kruithof E, Baeten D, ym.

Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. *Arthr Rheum* 2002; 46:755-65. [Kokotekstinä](#) OK*

[Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions.](#)

Van den Bosch F, Manger B, Goupille P, McHugh N, Rødevand E, Holck P, van Vollenhoven RF, Leirisalo-Repo M, Fitzgerald O, Kron M, Frank M, Kary S, Kupper H.

Ann Rheum Dis. 2010 Feb;69(2):394-9. Epub 2009 Oct 7. O [PDF](#) OK

MID: 19815494 [PubMed - indexed for MEDLINE] [Free PMC Article](#) [Free text](#) [Related citations](#)

Van de Putte LBA, R Rau, Breedveld FC, et al.

Efficacy and safety of the fully human anti-tumour necrosis factor {alpha} monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study

Ann Rheum Dis 2003; 62: 1168 - 77. [Kokotekstinä](#) OK*

Sitaatit on tarkoitettu 6.1.08

VAN DEN BRANDE JMH, PEPPELENBOSCH MP, VAN DEVENTER SJH
Treating Crohn's Disease by Inducing T Lymphocyte Apoptosis
Ann. N.Y. Acad. Sci. 2002; 973: 166 - 80. Otettu M 21.11.09 ja Otettu 13.10.12 [Ei oteta](#)

[\[Abstract\]](#) [\[Full Text\]](#) [\[PDF\]](#)

Van den Brande JM, Braat H, van den Brink GR et al
Hoedemaeker I, et al.
Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.
Gastroenterology 2003; 124: 1774-85. Otettu M 21.11.09 ja Otettu 13.10.12 [Ei oteta](#)

[Links](#)

Van den Brande JMH, Koehler TC, Zelinkova Z et al
Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.
Gut 2007; 56: 509-17 [Kokotekstiä](#) PDF [Ei oteta](#)

Vander Cruyssen B, Ribbens C, Boonen A.
The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice.
Ann Rheum Dis 2007;66:1072-7. Otettu M 21.11.09 [Ei oteta](#)
[\[Abstract/Free Full Text\]](#)

[Van der Bijl AE](#), Allaart CF, van Vugt JPP, ym.

Rheumatoid vasculitis treated with infliximab.

J Rheumatol 2005;32:1607-9. **OK***

van der Bijl AE, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, et al.

Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. *Arthritis Rheum* 2007; 56: 2129-34. **Ei oteta**

Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, van den Bosch F, et al. F

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity.

Arthritis Res Ther 2006;8:R112 Kokotekestinä **Ei oteta**

van der Heijde D, Klareskog L, Singh A, Tornero J, Melo-Gomes J, Codreanu C, Pedersen R, Freundlich B, Fatenejad S.

Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.

Ann Rheum Dis. 2006;65:328-34. doi: 10.1136/ard.2005.035709. [[PubMed](#)]

Otettu 7.9.2012 **Ei oteta**

[VAn der Heijde](#) , Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 582-91 [Kokotekstinä](#). [OK*](#)

van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al.
Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: 2-yr clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.
Arthritis Rheum (2006) 54:1063–74. [Kokotekstinä](#) [OK*](#)

van der Heijde D, Han C, De Vlam K, et al.
Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial.
Arthritis Rheum 2006;55:569–74. [Kokotekstinä](#) [Ei oteta](#)

van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2006) 54:2136–46. [Kokotekstinä](#) [OK](#)

[M](#)[\[CrossRef\]](#)[\[ISI\]](#)[\[Medline\]](#)

van der Heijde, D, Da Silva, J C, Dougados, M, Geher, P, van der Horst-Bruinsma, I, Juanola, X, Olivieri, I, Raeman, F, Settas, L, Sieper, J, Szechinski, J, Walker, D, Boussuge, M-P, Wajdula, J S, Paolozzi, L, Fatenejad, S, for the Etanercept Study 314 Investigators, (2006).

Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.

Ann Rheum Dis 65: 1572-1577

Otettu 7.9.2012 **OK**

- [\[Abstract\]](#)

van der Heijde D, Landewe R, Ory P, et al.

Two-year etanercept therapy does not inhibit radiographic progression in patients with ankylosing spondylitis.

Ann Rheum Dis (2006) 65(Suppl. II):8 **ei oteta**

van der Heijde D, Klareskog L, Baker P, Wajdula J, Fatenejad S. Etanercept combined with methotrexate is well tolerated for 3 years: results from the Trial of

Etanercept and Methotrexate with Radiographic and Patient Outcomes (TEMPO). *Ann*

Rheum Dis 2006;65:510. **Ei löydy eikä oteta**

van der Heijde D, Klareskog L, Landewé R, et al, for the TEMPO Study Investigators. Disease remission and sustained halting of radiographic progression with combination etanercept and

methotrexate in patients with rheumatoid arthritis. *Arthritis Rheum*
2007; 56: 3928–39 Otettu 18.6.18

[Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept.](#)

van der Heijde D, Landewé R, Einstein S, Ory P, Vosse D, Ni L, Lin SL, Tsuji W, Davis JC Jr.
Arthritis Rheum. 2008 May;58(5):1324-31. [Ei oteta](#)

PMID: 18438853 [PubMed - indexed for MEDLINE] Kokotekstinä
[PDF](#)

[Related Articles](#) [Free article at journal site](#)

van der Heijde D, Landewé R, Baraliakos X, et al.
Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis.
Arthritis Rheum 2008;58:3063-70. Otettu 13.10.12 [Ei oteta](#)

van der Heijde, D, Burmester, G, Melo-Gomes, J, Codreanu, C, Mola, E M., Pedersen, R, Freundlich, B, Chang, D J, for the Etanercept Study 400

Investigators, (2008). The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy. *Ann Rheum Dis* 67: 182-188 Otettu 20.10.12 **Ei oteta**

Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy.

van der Heijde D, Burmester G, Melo-Gomes J, Codreanu C, Martin Mola E, Pedersen R, Robertson D, Chang D, Koenig A, Freundlich B; Etanercept Study Investigators.

Ann Rheum Dis. 2009 Jul;68(7):1113-8. Epub 2008 Aug 21.

PMID: 18718986 [PubMed - indexed for MEDLINE] Otettu 13.10.12

Related Articles

Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis.

van der Heijde DM, Revicki DA, Gooch KL, Wong RL, Kupper H, Harnam N, Thompson C, Sieper J; ATLAS Study Group.

Arthritis Res Ther. 2009;11(4):R124. Kokotekstinä [PDF](#)

Otettu 28.10.16

Epub 2009 Aug 17. MPMID: 19686597 [PubMed - indexed for MEDLINE][Free PMC Article](#)[Free text](#)[Related citations](#)

[Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.](#)

van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, Dijkmans BA, Mease PJ, Davis JC Jr; ATLAS Study Group.

Ann Rheum Dis. 2009 Jun;68(6):922-9. [Kokotekstinä](#) [Ei oteta](#)

Epub 2008 Aug 13. PMID: 18701556 [PubMed - indexed for MEDLINE][**Free PMC Article**](#)[Free text](#)[Related citations](#)

[Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years.](#)

van der Heijde D, Salonen D, Weissman BN, Landewé R, Maksymowych WP, Kupper H, Ballal S, Gibson E, Wong R; Canadian (M03-606) study group; ATLAS study group.

Arthritis Res Ther. 2009;11(4):R127. Epub 2009 Aug 24. Otettu 13.10.12

[Ei oteta](#)

19703304 [PubMed - indexed for MEDLINE][**Free PMC Article**](#)[Free text](#)[Related citations](#)

[Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial.](#)

van der Heijde D, Braun J, Dougados M, Sieper J, Pedersen R, Szumski A, Koenig AS.

Rheumatology (Oxford). 2012 Jul 6. [Epub ahead of print] [Ei oteta](#)

PMID:

Otettu 20.10.12

22772319

[PubMed - as supplied by publisher]

[Related citations](#)

[Spinal inflammation in the absence of sacroiliac joint inflammation on magnetic resonance imaging in patients with active nonradiographic axial spondyloarthritis.](#)

van der Heijde D, Sieper J, Maksymowycz WP, Brown MA, Lambert RG, Rathmann SS, Pangan AL.

Arthritis Rheumatol. 2014 Mar;66(3):667-73. doi: 10.1002/art.38283.

PMID:

24574227

[PubMed - indexed for MEDLINE] Otettu 28.10.16

[Free PMC Article](#)

[Related citations](#)

[Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial.](#)

van der Heijde D, Sieper J, Maksymowycz WP, Lambert RG, Chen S, Hojnik M, Anderson JK, Pangan AL.

Arthritis Res Ther. 2018 Mar 27;20(1):61. doi: 10.1186/s13075-018-1556-5.

PMID:

29587851 Ota kotona

[Free PMC Article](#)

[Similar articles](#)

van der Horst-Bruinsma I, Wanders A, van der Heijde D, Fatenejad S. Radiographic results from a long-term multicenter trial of etanercept in patients with ankylosing spondylitis.

Rheumatology (2006) 45:i5. Ei oteta

[\[Free Full Text\]](#)

1191.

[Chronic signs of memory B cell activation in patients with Behçet's disease are partially restored by anti-tumour necrosis factor treatment.](#)

van der Houwen TB, van Hagen PM, Timmermans WM, Bartol SJ, Lam KH, Kappen JH, van Zelm MC, van Laar JA.

Rheumatology (Oxford). 2017 Jan;56(1):134-144. doi: 10.1093/rheumatology/kew366. Epub 2016 Oct 15.

PMID:

27744360 Otettu 18.6.18

[Similar articles](#)

Van Der Klooster J M, Bosman R J, Oudemans-van Straaten H M et al
Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate.
Intensive Care Med 2003;29:2327–9. Otettu 13.10.12 [Ei oteta](#)

[\[CrossRef\]](#)[\[Medline\]](#)

Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis

van der Kooij et al.

Ann Rheum Dis 2009;68:1153-1158. Otettu 18.6.18

[Van der Laken C J](#), Lems W F, van Soesbergen R M, et al.

Paraplegia in a patient receiving anti-tumor necrosis factor therapy for rheumatoid arthritis: Comment on the article by Mohan, et al.

Arthritis Rheum 2003;48:269–70 [Kokotekstinä](#). [OK*](#)

van der Laken, C J, Voskuyl, A E, Roos, J C, Stigter van Walsum, M, de Groot, E R, Wolbink, G, Dijkmans, B A C, Aarden, L A (2007). Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis

S. Ann Rheum Dis 66: 253-256 Otettu 13.10.12 [Ei oteta](#)

- [\[Abstract\]](#) [\[Full Text\]](#)

[Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge.](#)

van der Stoep D, Braunstahl GJ, van Zeben J, Wouters J.

J Rheumatol. 2009 Dec;36(12):2847-8. [Kokotekstinä](#)

No abstract available. PMID: 19966199 [PubMed - indexed for MEDLINE][Related citations](#)

[OK](#)

van der Vaart, H., Koeter, G. H., Postma, D. S., Kauffman, H. F., ten Hacken, N. H. T.

(2005).

First Study of Infliximab Treatment in Patients with Chronic Obstructive Pulmonary Disease.

Am J Respir Crit Care Med 172: 465-469

[Kokotekstinä](#) OK

- [\[Abstract\]](#) [\[Full Text\]](#)

[IBD: Exposure to anti-TNF agents in utero: controlling health risks.](#)

van der Woude CJ, Kanis SL.

Nat Rev Gastroenterol Hepatol. 2016 Jul;13(7):387-8. doi: 10.1038/nrgastro.2016.94. Epub 2016 Jun 2. No abstract available.

PMID:

27251210 Otettu 18.6.18

[Similar articles](#)

[Adalimumab \(antitumour necrosis factor- \$\alpha\$ \) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study.](#)

van der Zee HH, Laman JD, de Ruiter L, Dik WA, Prens EP.

Br J Dermatol. 2012 Feb;166(2):298-305. doi: 10.1111/j.1365-2133.2011.10698.x.

Otettu 13.10.12 Ei oteta

PMID:

22013960

[PubMed - indexed for MEDLINE]

[Related citations](#)

323.

[Etanercept Increases Bone Mineral Density in Ankylosing Spondylitis, but Does Not Prevent Vertebral Fractures: Results of a Prospective Observational Cohort Study.](#)

van der Weijden MA, van Denderen JC, Lems WF, Nurmohamed MT, Dijkmans BA, van der Horst-Bruinsma IE.

J Rheumatol. 2016 Apr;43(4):758-64. doi: 10.3899/jrheum.150857. Epub 2016 Feb 15.

PMID:

26879348 Otettu 18.6.18

[Similar articles](#)

Van Deventer SJ.

Tumour necrosis factor and Crohn's disease

. Gut 1997;40:443–8. **Otettu**

[\[Free Full Text\]](#)

[Van Deventer SJH.](#) Anti-TNF antibody treatment of Crohn's disease. Ann Rheum Dis 1999;58:114-120 [Kokotekstinä *](#)

Van Deventer SJ. Transmembrane TNF-, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology 2001; 121: 1242-6.

Otettu 13.10.12

[Links](#)

Van Deventer SJH

Anti-tumour necrosis factor therapy in Crohn's disease: where are we now?

Gut 2002; 51: 362 - 3. [Kokotekstinä *](#)

Van Doornum SV, McColl G, Wicks IP

Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis

Rheumatology 2005; 44: 1428 - 32. Ref. tarkistettu 29.2.0 8 [Kokotekstinä](#)

Ei oteta

[\[Abstract\]](#) [\[Full Text\]](#) [\[PDF\]](#)

van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129–35

Otettu 13.10.12 Ei oteta

.[\[Medline\]](#)

I C van Eijk, M J L Peters, M T Nurmohamed, A W van Deutekom, B A C Dijkmans, and S Simsek

Decrease of fructosamine levels during treatment with adalimumab in patients with both diabetes and rheumatoid arthritis

Eur. J. Endocrinol., March 1, 2007; 156(3): 291 - 293. Otettu 20.10.12

[\[Abstract\]](#) [\[Full Text\]](#) [\[PDF\]](#)

[Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis.](#)

van Eijk IC, de Vries MK, Levels JH, Peters MJ, Huizer EE, Dijkmans BA, van der Horst-Bruinsma IE, Hazenberg BP, van de Stadt RJ, Wolbink GJ, Nurmohamed MT.

Arthritis Rheum. 2009 May;60(5):1324-30.

PMID: 19404933 [PubMed - indexed for MEDLINE] [Kokotekstinä](#)

[Related Articles](#)

[Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade.](#)

van Eijk IC, Peters MJ, Serné EH, van der Horst-Bruinsma IE, Dijkmans BA, Smulders YM, Nurmohamed MT.

Ann Rheum Dis. 2009 Mar;68(3):362-6. Epub 2008 Apr 4.

PMID: 18390569 [PubMed - indexed for MEDLINE] Otettu m 12.11.09

[Related Articles](#)

[Randomized, placebo controlled and double-blind trials of efficacy and safety of adalimumab for treating ankylosing spondylitis: a meta-analysis.](#)

Wang H, Zuo D, Sun M, Hua Y, Cai Z.

Int J Rheum Dis. 2014 Feb;17(2):142-8. doi: 10.1111/1756-185X.12245. Epub 2014 Feb 8.

PMID:

24506823

[PubMed - in process] [Kokotekstinä](#)

[Related citations](#)

14.

[The use of biologic therapies in the treatment of rheumatoid arthritis.](#)

Wang D, Li Y, Liu Y, Shi G.

Curr Pharm Biotechnol. 2014;15(6):542-8.

PMID:

25213363

[PubMed - in process] [ei ole M](#)

[Related citations](#)

[Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial.](#)

Wang J.

J Int Med Res. 2018 Jan;46(1):326-334. doi: 10.1177/0300060517723182. Epub 2017 Aug 25.

PMID:

28840750 Otettu 18.6.18

[Similar articles](#)

[TNF blockade requires 1,25\(OH\)2D3 to control human Th17-mediated synovial inflammation.](#)

van Hamburg JP, Asmawidjaja PS, Davelaar N, Mus AM, Cornelissen F, van Leeuwen JP, Hazes JM, Dolhain RJ, Bakx PA, Colin EM, Lubberts E.

Ann Rheum Dis. 2012 Apr;71(4):606-12. Epub 2012 Jan 4.

PMID:

22219138 Otettu 13.10.12

[PubMed - indexed for MEDLINE]

[Related citations](#)

525.

[Adalimumab and etanercept serum \(anti\)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis.](#)

van Herwaarden N, Bouman CA, van der Maas A, van Vollenhoven RF, Bijlsma JW, van den Hoogen FH, den Broeder AA, van den Bemt BJ.

Ann Rheum Dis. 2015 Dec;74(12):2260-1. doi: 10.1136/annrheumdis-2015-207814. No abstract available.

PMID:

26342093 Otettu 18.6.18

[Similar articles](#)

Vanhoof J, Landewe S, Van Wijngaerden E, ym.

High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitor
s. Ann Rheum Dis 2003;62:1241-2. Kokotekstinä *

Efficacy of etanercept in ankylosing spondylitis hip lesions.

Wang D, Ma L, Wu D.

Joint Bone Spine. 2011 Oct;78(5):531-2. Epub 2011 May 12. No abstract available.

PMID:

21570332 Otettu 18.6.18

[PubMed - indexed for MEDLINE]

Related citations

Treatment with etanercept in a patient with rheumatoid arthritis-associated interstitial lung disease.

Wang Y, Xu SQ, Xu JH, Ding C.

Clin Med Insights Case Rep. 2011;4:49-52. Epub 2011 Oct 6. Kokotekstinä

Ei oteta

[\[PubMed\]](#)
Free PMC Article
[Related citations](#)

[**Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin \(IL\)-19, IL-20 and IL-24.**](#)

Wang F, Smith N, Maier L, Xia W, Hammerberg C, Chubb H, Chen C, Riblett M, Johnston A, Gudjonsson JE, Helfrich Y, Kang S, Fisher GJ, Voorhees JJ.

Br J Dermatol. 2012 Jul;167(1):92-102. doi: 10.1111/j.1365-2133.2012.10961.x.

PMID:

Otettu 13.10.12 [Ei oteta](#)

22458549

[PubMed - in process]

[Related citations](#)

[**Occurrence of psoriatic plaques on previous adalimumab injection sites during disease relapse in a patient with pustular psoriasis.**](#)

Wang TS, Tsai TF.

J Am Acad Dermatol. 2014 Jul;71(1):e24-6. doi: 10.1016/j.jaad.2013.12.020. No abstract available.

PMID:

24947709

[PubMed - in process] Otettu 28.10.16

[Free Article](#)

[Related citations](#)

[The use of biologic therapies in the treatment of rheumatoid arthritis.](#)

Wang D, Li Y, Liu Y, Shi G.

Curr Pharm Biotechnol. 2014;15(6):542-8.

PMID:

25213363

[PubMed - in process] ei ole M

[Related citations](#)

819.

[Successful Treatment of Refractory Juvenile Dermatomyositis With Adalimumab.](#)

Wang CR.

J Clin Rheumatol. 2017 Apr;23(3):174-175. doi: 10.1097/RHU.0000000000000514. No abstract available.

PMID:

28333871 Otettu 18.6.18

[Similar articles](#)

[Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis.](#)

van Kuijk AW, de Groot M, Stapel SO, Dijkmans BA, Wolbink GJ, Tak PP.
Ann Rheum Dis. 2010 Mar;69(3):624-5. No abstract available. Otettu
20.10.12 **OK**

MPMID: 20223840 [PubMed - indexed for MEDLINE][Related citations](#)

J A M van Laar, T Missotten, P L A van Daele, A Jamnitski, G S Baarsma, and P M van Hagen

Adalimumab: a new modality for Behcet's disease?

Ann Rheum Dis, April 1, 2007; 66(4): 565 - 566. Otettu m 12.11.09 Ei oteta
[\[Full Text\]](#) [\[PDF\]](#)

van Lieshout, A W T, Barrera, P, Smeets, R L, Pesman, G J, van Riel, P L C M, van den Berg, W B, Radstake, T R D J (2005)

Inhibition of TNF{alpha} during maturation of dendritic cells results in the development of semi-mature cells: a potential mechanism for the beneficial effects of TNF{alpha} blockade in rheumatoid arthritis

. Ann Rheum Dis 64: 408-414 Otettu M 12.11.09 **Ei oteta**

- [\[Abstract\]](#) [\[Full Text\]](#)

van Lieshout AW, Creemers MC, Radstake TR, Elving LD, van Riel PL.

Graves' disease in a patient with rheumatoid arthritis during treatment with anti-tumor necrosis factor- α [letter].

J Rheumatol 2008;35:938-9. Otettu 13.10.12 Ei oteta

Relevance of compartmentalization of T-cell subsets for clinical improvement in psoriasis: effect of immune-targeted antipsoriatic therapies.

van Lingen RG, Körver JE, van de Kerkhof PC, Berends MA, van Rens DW, Langewouters AM, Boezeman JB, Seyger MM, de Jong EM.

Br J Dermatol. 2008 Jul;159(1):91-6. Epub 2008 Jul 1.

PMID: 18476954 [PubMed - indexed for MEDLINE] Otettu M 12.11.09

9 Ei oteta

Related Articles

Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.

Van Lü mig PP, Lecluse LL, Driessen RJ, Spuls PI, Boezeman JB, van de Kerkhof PC, De Jong EM.

Br J Dermatol. 2010 Oct;163(4):838-46. doi: Otettu 18.6.18
10.1111/j.1365-2133.2010.09950.x. Epub 2010 Sep 2.

PMID: 20649798 [PubMed - in process]

[Related citations](#)

[Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients.](#)

van Lü mig PP, van de Kerkhof PC, Boezeman JB, Driessen RJ, de Jong EM.

J Eur Acad Dermatol Venereol. 2012 Mar 15. doi: 10.1111/j.1468-3083.2012.04496.x. [Epub ahead of print]

PMID: Otettu 13.10.12 [Ei oteta](#)

22416818

[PubMed - as supplied by publisher]

[Related citations](#)

190.

van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH:

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

Neurology 1996, 47:1531-1534. Otettu 18.6.18

Van Oosterhout M, Levarht EWN, Sont JK et al

Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial

expression of TNF{alpha} and IL18 but not CXCL12
Ann Rheum Dis 2005; 64: 537 - 43. Otettu M 12.11.09
Ei oteta [\[Abstract\]](#) [\[Full Text\]](#) [\[PDF\]](#)

Van Riel PLC, van de Putte LBA, Rau R et.al.
Long term treatment with Adalimumab (D2E7) using background methotrexate is active rheumatoid arthritis: Results of a 3-year study. Arthr Rheum 2002; 9(Suppl):S534

ei löydy eikä oteta

Van Riel PLCM, Taggart AJ, Sany J et al
Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study.

Ann Rheum Dis 2006; 65:1478–83. Otettu 20.10.12

Sitaatit tarkistettu 29.4.08

van Riel, P L C M, Freundlich, B, MacPeek, D, Pedersen, R, Foehl, J R, Singh, A, on behalf of ADORE study investigators, (2008). Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial.
Ann Rheum Dis 67: 1104-1110 Otettu M 12.11.09 **Ei oteta**

- [\[Abstract\]](#) [\[Full Text\]](#)
-

J. A G van Roon, S. A Y Hartgring, M. Wenting-van Wijk, K. M G Jacobs, P.-P. Tak, J. W J Bijlsma, and F. P J G Lafeber

Persistence of interleukin 7 activity and levels on tumour necrosis

factor {alpha} blockade in patients with rheumatoid arthritis

Ann Rheum Dis, May 1, 2007; 66(5): 664 - 669. Otettu M 12.11.09

[\[Abstract\]](#) [\[Full Text\]](#) [\[PDF\]](#)

[A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients.](#)

van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D.

J Immunol Methods. 2010 Oct 31;362(1-2):82-8.

Epub 2010 Sep 9. Otettu 13.10.12 Ei oteta

MPMID: 20833178 [PubMed - indexed for MEDLINE][Related citations](#)

[Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.](#)

van Schouwenburg PA, van de Stadt LA, de Jong RN, van Buren EE, Kruithof S, de Groot E, Hart M, van Ham SM, Rispens T, Aarden L, Wolbink GJ, Wouters D.

Ann Rheum Dis. 2012 Jul 3. [Epub ahead of print] ei oteta

PMID:

22759910

[PubMed - as supplied by publisher]

[Related citations](#)

[IgG4 Production Against Adalimumab During Long Term Treatment of RA Patients.](#)

van Schouwenburg PA, Krieckaert CL, Nurmohamed M, Hart M, Rispens T, Aarden L, Wouters D, Wolbink GJ.

J Clin Immunol. 2012 May 24. [Epub ahead of print] Otettu 20.10.12 OK

PMID:

22622790

[PubMed - as supplied by publisher]

[Related citations](#)

[Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis.](#)

van Schoouwenburg PA, Rispens T, Wolbink GJ.

Nat Rev Rheumatol. 2013 Mar;9(3):164-72. doi: 10.1038/nrrheum.2013.4.

Epub 2013 Feb 12.

PMID:

23399692

[PubMed - in process] Otettu 18.6.18

[Related citations](#)

van Tubergen A , van der Heijde D, Anderson J et al

Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel.

Ann Rheum Dis 2003;62:215–21. [Kokotekstinä](#) [Ei oteta](#)

Sitaatit tarkistettu 29.4.08

[Severe cholestasis due to disseminated histoplasmosis under adalimumab-containing immunosuppressive therapy.](#)

van Welzen BJ, van Erpecum KJ, Haas PJ, Ten Kate FJ, Mudrikova T.

Clin Res Hepatol Gastroenterol. 2013 May 7. doi:pii: S2210-7401(13)00059-4.

10.1016/j.clinre.2013.03.008. [Epub ahead of print] No abstract available.

PMID:

23663920

[PubMed - as supplied by publisher] Otettu 18.6.18

[Related citations](#)

van Vollenhoven R F, Klareskog L.

Clinical responses to tumor necrosis factor α antagonists do not show a bimodal distribution. Data from the Stockholm tumor necrosis factor α registry

. Arthritis Rheum 2003;48:1500–3. Otettu M 12.11.09

[CrossRef][Medline] **Ei oteta**

Van Vollenhoven R, Harju A, Brannemark S, et al. (2003). Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor $\{\alpha\}$ blockers can make sense.

Ann Rheum Dis 62: 1195-1198 Kokotekstinä * **OK**

Sitaatit tarkistettu 13.12.2008

van Vollenhoven RF, Ernestam S, Harju A, Bratt J, Klareskog L.

Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious.

Arthritis Res Ther 2003;5:R347-R351. Otettu M 12.11.09 **Ei oteta**

van Vollenhoven RF. Benefits and risks of biological agents: lymphomas. Clin Exp Rheumatol. 2004;22(5)(suppl 35):S122-S125. Otettu 13.10.12 **Ei oteta**

van Vollenhoven RF. Switching between biological agents.

Clin Exp Rheumatol 2004;22(suppl 35):S115-21.
Otettu 12.6.18

van Vollenhoven R F, Brannemark S, Klareskog L. Dosage escalation of infliximab in clinical practice: a registry-based study suggesting that improvements seen after infliximab dosage escalation are largely explained by a regression-like effect. *Ann Rheum Dis* 2004;63:426–30. Otettu M 12.11.09 **Ei oteta**

[\[Abstract/Free Full Text\]](#)

van Vollenhoven RF

Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue

Ann Rheum Dis 2007; 66: 849 - 51. [Kokotekstinä](#) **Ei oteta**

Ref. tarkistettu 9.2.08

[American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial.](#)

van Vollenhoven RF, Felson D, Strand V, Weinblatt ME, Luijten K, Keystone EC.

Arthritis Care Res (Hoboken). 2011 Jan;63(1):128-34. doi: 10.1002/acr.20331.

[Kokotekstinä](#) **Ei oteta**

PMID:

20799264

[PubMed - indexed for MEDLINE]

[Related citations](#)

Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B; ORAL Standard Investigators.

N Engl J Med. 2012 Aug 9;367(6):508-19. Otettu 13.10.12 [ei oteta](#)

PMID:

22873531

[PubMed - in process]

[Related citations](#)

504.

Rheumatoid arthritis. Triple therapy or etanercept after methotrexate failure in RA?

van Vollenhoven RF, Chatzidionysiou K.

Nat Rev Rheumatol. 2013 Sep;9(9):510-2. doi: 10.1038/nrrheum.2013.118. Epub 2013 Jul 30.

PMID:

23897440

[PubMed - indexed for MEDLINE] Otettu 18.6.18

[Related citations](#)

Adalimumab-induced lupus erythematosus with central nervous system involvement in a patient with Crohn's disease.

Vannucchi V, Grazzini M, Pieralli F, Giannotta M, Biagioni C, Nozzoli C.

J Gastrointestin Liver Dis. 2011 Jun;20(2):201-3. [Kokotekstinä](#)

PMID:

OK

21725519

[PubMed - indexed for MEDLINE]

[Free Article](#)

[Related citations](#)

Ward, M M

Outcomes in ankylosing spondylitis: what makes the assessment of treatment effects in ankylosing spondylitis different?.

Ann Rheum Dis 2006; 65: iii25-iii28 Otettu M 12.11.09 [Ei oteta](#)

- [\[Abstract\]](#) [\[Full Text\]](#)

M. M Ward

Interpreting measurements of physical function in clinical trials

Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii32 - iii34. Otettu M 12.11.09 [Ei oteta](#)

[\[Abstract\]](#) [\[Full Text\]](#) [\[PDF\]](#)

497

[American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.](#)

Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, Smith JA, Borenstein D, Hiratzka J, Weiss PF, Inman RD, Majithia V, Haroon N, Maksymowych WP, Joyce J, Clark BM, Colbert RA, Figgie MP, Hallegua DS, Prete PE, Rosenbaum JT, Stebulis JA, van den Bosch F, Yu DT, Miller AS, Reveille JD, Caplan L.

Arthritis Rheumatol. 2016 Feb;68(2):282-98. doi: 10.1002/art.39298.

PMID:

26401991 Otettu 18.6.18

[Similar articles](#)

174.

[Adalimumab-Induced Epstein-Barr Virus-Related Lymphoproliferative Disorder on FDG PET/CT.](#)

Ward J, Noy A, Ulaner G, Riedl C.

Clin Nucl Med. 2018 May;43(5):344-345. doi: 10.1097/RLU.0000000000002054.

PMID:

29538028 Otettu 18.6.18

[Similar articles](#)

1011.

[Etanercept versus monoclonal antibodies in axial spondyloarthritis: game over?](#)

Varkas G, Elewaut D.

J Rheumatol. 2014 Oct;41(10):1899-902. doi: 10.3899/jrheum.140866. No abstract available.

PMID:

25275090 Otettu 18.6.18

[Similar articles](#)

[Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis.](#)

Warner B, Harris AW.

Gastroenterology. 2012 Jul;143(1):e42. Epub 2012 May 24. No abstract available. Otettu

20.10.12 **Ei oteta**

PMID:

22634354

[PubMed - in process]

[Related citations](#)

[Warris A, Bjorneklett A, Gaustad P: Invasive pulmonary aspergillosis associated with infliximab therapy.](#)

[N Engl J Med](#) 2001, 344:1099-100. **OK**

[Adalimumab for the treatment of inflammatory bowel disease.](#)

Wasan SK, Kane SV.

Expert Rev Gastroenterol Hepatol. 2011 Dec;5(6):679-84. **ei ole M**

PMID:

22017695

[PubMed - indexed for MEDLINE]

[Related citations](#)

Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis.

Vasconcellos JB, Pereira DD, Vargas TJ, Levy RA, Pinheiro GD, Cursi ÍB.

An Bras Dermatol. 2016 Sep-Oct;91(5 suppl 1):137-139. doi: 10.1590/abd1806-4841.20164456.

PMID:

28300922 Ota kotona

[Free PMC Article](#)

[Similar articles](#)

Vasiliauskas EA, Church JA, Silverman N, et al
Case report: evidence for trans-placental transfer of maternally administered infliximab to the newborn.

Clin Gastroenterol Hepatol 2006;4:1255-8 Otettu M 12.11.09 OK

Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population.

Vasilopoulos Y, Manolika M, Zafiriou E, Sarafidou T, Bagiatis V, Krüger-Krasagaki S, Tosca A, Patsatsi A, Sotiriadis D, Mamuris Z, Roussaki-Schulze A. Ei ole

Mol Diagn Ther. 2012 Feb 1;16(1):29-34. doi: 10.2165/11594660-000000000-00000.

PMID:

22111980

[PubMed - indexed for MEDLINE]

[Related citations](#)

Vassallo R, Matteson E, Thomas CF. Clinical Response of Rheumatoid

Arthritis-Associated Pulmonary Fibrosis to Tumor Necrosis Factor-[alpha] Inhibition.
Chest 2002;122:1093-6. [Kokotekstinä](#) Otettu 18.6.18

[**Adalimumab decreases aortic stiffness independently of its effect in disease activity in patients with rheumatoid arthritis.**](#)

Vassilopoulos D, Gravos A, Vlachopoulos C, Kandili A, Ioakeimidis N, Pectasides D, Stefanadis C.

Clin Rheumatol. 2014 Jun 15. [Epub ahead of print]

PMID:

24928345

[PubMed - as supplied by publisher] Otettu 18.6.18

[Related citations](#)

Select item 23270195136.

[**Adalimumab for the treatment of pityriasis rubra pilaris: a case report.**](#)

Wassef C, Lombardi A, Rao BK.

Cutis. 2012 Nov;90(5):244-7.

PMID:

23270195

[PubMed - indexed for MEDLINE] ei ole M

[Related citations](#)

Wasserman MJ, Weber DA, Guthrie JA, Bykerk VP,
Lee P, Keystone

EC. Infusion-related reactions to infliximab in
patients with rheumatoid
arthritis in a clinical practice setting: relationship to
dose, anti-histamine
pre-treatment, and infusion number. J Rheumatol
2004;31:1912-7. M **Ei oteta**

[Anti-tumour-necrosis-factor-alpha agents and the heart: beyond left ventricular systolic dysfunction?](#)

Vassiliou V, Ntatsaki E.

N Z Med J. 2011 Sep 23;124(1343):76-8. No abstract available. Otettu 20.10.12 **Ei oteta**

PMID:

21964016

[PubMed - indexed for MEDLINE]

[Related citations](#)

Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis AJ.
Usefulness of enzyme-linked immunospot assay (Elispot) compared
to tuberculin skin testing for latent tuberculosis screening in
rheumatic patients scheduled for anti-tumor necrosis factor

treatment. J Rheumatol 2008;35:1271-6.

Otettu 13.10.12 [Ei oteta](#)

[Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.](#)

Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, Manesis EK, Archimandritis AI.

Ann Rheum Dis. 2010 Jul;69(7):1352-5. Epub 2010 May 14. Otettu 18.6.18
PMID:

20472596

[PubMed - indexed for MEDLINE]

[Related citations](#)

[Subacute thyroiditis presenting as fever of unknown origin in a patient with rheumatoid arthritis under etanercept treatment.](#)

Vassilopoulos D, Sialevis K, Malahtari S, Deutsch M, Manolakopoulos S, Archimandritis AJ.

J Clin Rheumatol. 2010 Mar;16(2):88-9. No abstract available. Otettu 13.10.12 [Ei oteta](#)

PMID:

20216130

[PubMed - indexed for MEDLINE]

[Related citations](#)

Etanercept-Induced Pneumonitis: Severe Complication of Tumor Necrosis Factor-Alpha Blocker Treatment.

Watad A, Perelman M, Mansour R, Shoenfeld Y, Amital H.

Isr Med Assoc J. 2015 Feb;17(2):130-2. No abstract available.

PMID:

26223096 Otettu 28.10.16

[Free Article](#)

[Similar articles](#)

Clinical characteristics and risk factors for
Pneumocystis jirovecii pneumonia in patients with
rheumatoid arthritis receiving **adalimumab**: a
retrospective review and case-control study of 17
patients.

Watanabe K, Sakai R, Koike R, Sakai F, Sugiyama H, Tanaka M, Komano Y, Akiyama Y, Mimura T, Kaneko M, Tokuda H, Iso T, Motegi M, Ikeda K, Nakajima H, Taki H, Kubota T, Kodama H, Sugii S, Kuroiwa T, Nawata Y, Shiozawa K, Ogata A, Sawada S, Matsukawa Y, Okazaki T, Mukai M, Iwahashi M, Saito K, Tanaka Y, Nanki T, Miyasaka N, Harigai M.

Mod Rheumatol. 2012 Dec 5. [Epub ahead of print]

PMID:

23212592

[PubMed - as supplied by publisher] Otettu 18.6.18

Related citations

581.

Anti-tumour necrosis factor agents reduce non-steroidal anti-inflammatory drug-induced small bowel injury in rheumatoid arthritis patients.

Watanabe T, Tanigawa T, Shiba M, Nadatani Y, Nagami Y, Sugimori S, Yamagami H, Watanabe K, Tominaga K, Fujiwara Y, Koike T, Arakawa T.

Gut. 2014 Mar;63(3):409-14. doi:
10.1136/gutjnl-2013-304713. Epub 2013 May 22.

PMID:

23697473

[PubMed - indexed for MEDLINE] Otettu 18.6.18

Related citations

Watson D J, Rhodes T, Guess H A.

All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database.

J Rheumatol 2003;30:1196–202. Otettu 13.10.12 **Ei oteta**

[\[Medline\]](#)

Watson K, Hyrich K, Symmons D, Silman A and the BSR Biologics. British Society for Rheumatology Biologics Register (BSRBR): the experience of rheumatoid arthritis patients receiving infliximab or etanercept to December 2003. *Rheumatology*

2004;43(Supplement 2):ii1. **ei oteta**

Watson KD, Dixon WG, Hyrich KL, et al. Influence of anti-TNF therapy and previous malignancy on cancer incidence in patients with rheumatoid arthritis (RA): results from the BSR Biologics Register (BSRBR). *Rheumatology (Oxford)* 2006; 45:i10-i12. **Ei löytynyt M netistä**

[Management of accelerated pulmonary nodulosis following etanercept therapy in a patient with rheumatoid arthritis.](#)

Watson P, Simler N, Scream N, Lillicrap M.

Rheumatology (Oxford). 2008 Jun;47(6):928-9. Epub 2008 Apr 2. No abstract available.

PMID: 18385217 [PubMed - indexed for MEDLINE] Otettu m 12.11.0

9 [Kokotekstinä](#) [Ei oteta](#)

[Related Articles](#)

[Response to 'Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial'.](#)

Watson P, Gaston H.

Arthritis Res Ther. 2011;13(2):403. No abstract available.

PMID:

21542877 [Kokotekstinä](#) [OK](#)

[PubMed - indexed for MEDLINE]

[Free PMC Article](#)

[Related citations](#)

[Histiocytoid Sweet syndrome successfully treated with etanercept.](#)

Watson IT, Haugh I, Gardner AR, Menter MA.

Proc (Bayl Univ Med Cent). 2018 May 9;31(3):347-349. doi: 10.1080/08998280.2018.1460132. eCollection 2018 Jul.

PMID:

29904308 Ota kotona

[**Free PMC Article**](#)

[Similar articles](#)

Vauloup C, Krzysiek R, Greangeot-Keros L et al. Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities. Eur Cytokine Netw 2006; 17:290–3. **Ei ole M netissä**

[Vavricka SR](#), Wetstein T, Speich R,ym.

Pulmonary granulomas after tumour necrosis factor alpha antagonist therapy.

Thorax 2003;58:278-9. **OK***

[Kokotekstinä](#)

[Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey.](#)

Vavricka SR, Schoepfer AM, Bansky G, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Scharl M, Seibold F, Straumann A, Michetti P; Swiss IBDnet.

Inflamm Bowel Dis. 2011 Jul;17(7):1530-9. doi: 10.1002/ibd.21521. Epub 2010 Dec 22. **Otettu**

18.6.18

PM

21674709

[PubMed - indexed for MEDLINE]

[Related citations](#)

[Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study.](#)

Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N, Juillerat P, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Heinrich H, Manser CN, Safroneeva E, Raja Ali RA, Rogler G, Schoepfer AM, Greuter T; Swiss IBD Cohort Study Group.

Inflamm Bowel Dis. 2017 Jul;23(7):1174-1181. doi: 10.1097/MIB.0000000000001109.

PMID:

28452862 Ota kotona

[Free Article](#)

[Similar articles](#)

Vazquez-Cobian LB, Flynn T, Lehman TJ.
Adalimumab therapy for childhood uveitis.
J Pediatr 2006;149:572-5. ei oteta

2003;Veale D, Markham T, Fearon U, Rogers S, Golden-Mason L, Bresnihan B, et al.
Anti-TNF alpha therapy in psoriasis and psoriatic arthritis: clinical and angiogenic
responses. Arthritis Rheum 48:S168. **ei löydy eikä oteta**

Weaver AL. The impact of new biologicals in the treatment of rheumatoid arthritis. *Rheumatology (Oxford)* 2004;43 Suppl 3:iii17–23.25. Otettu M 12.11.09 **ei oteta**

[Pregnancy outcome after TNF- \$\alpha\$ inhibitor therapy during the first trimester: a prospective multicentre cohort study.](#)

Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N; network of French pharmacovigilance centres., Beghin D, Cuppers-Maarschalkerweerd B, Richardson JL, Rothuizen LE, Pistelli A, Malm H, Eleftheriou G, Kennedy D, Kadioglu Duman M, Meister R, Schaefer C.

Br J Clin Pharmacol. 2015 Oct;80(4):727-39. doi: 10.1111/bcp.12642.

PMID:

25808588 Otettu 28.10.16

[Free PMC Article](#)

[Similar articles](#)

Wechsler B, Sable-Fourtassou R, Bodaghi B, et al
. Infliximab in refractory uveitis
due to Behcet's disease.

Clin Exp Rheumatol 2004;22:S14–16.

[Kokotekstinä \(PDF\)](#)

Poimittu koneelle 1.10.09 **OK**

Review article: the effects of antitumour necrosis factor- α on bone metabolism in inflammatory bowel disease.

Veerappan SG, O'Morain CA, Daly JS, Ryan BM.

Aliment Pharmacol Ther. 2011 Jun;33(12):1261-72. doi: 10.1111/j.1365-2036.2011.04667.x. Epub 2011 Apr 26. Review.

PMID:

Otettu 18.6.18

21521250

[PubMed - indexed for MEDLINE]

Related citations

Wegscheider BJ, El-Shabrawi L, Weger M, et al. Adverse skin reactions to infliximab in the treatment of intraocular inflammation.

Eye 2007; 21: 547-9. Otettu M 12.11.09 **OK**

C. Wenham, K. Gadsby, and C. Deighton

Three significant cases of neutropenia with etanercept

Rheumatology, March 1, 2008; 47(3): 376 - 377. Otettu M 12.11.09

[Full Text] [PDF] **Ei oteta**

[Adalimumab \(TNF α Inhibitor\) Therapy Exacerbates IgA Glomerulonephritis Acute Renal Injury and Induces Lupus Autoantibodies in a Psoriasis Patient.](#)

Wei SS, Sinniah R.

Case Rep Nephrol. 2013;2013:812781. doi: 10.1155/2013/812781. Epub 2013 Jul 24.

PMID:

24558628 Otettu 28.10.16

[PubMed]

[Free PMC Article](#)

[Related citations](#)

[Weinblatt ME](#), Kremer JM, Bankhurst AD, ym.

A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor: Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate

[N Eng J Med](#) 1999; 340:253-9. * OK

Sit.tarkistettu 14.12.08

[Weinblatt ME](#), Keystone EC, Furst DE, ym. Adalimumab, a fully human anti-tumor necrosis factor alfa monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthr Rheum 2003; 48:35-45. Kokotekstinä OK

Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. *Arthritis Rheum* 2003;48:35–45 erratum in *Arthritis Rheum* 2003;48:855 *Arthritis Rheum* 2004;22:144. Otettu M 12.11.09

Ei oteta

[\[CrossRef\]](#) [\[Medline\]](#)

Weinblatt ME, Keystone EC, Furst DE et al
Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study
Ann Rheum Dis 2006; 65: 753 - 9. [Kokotekstinä](#) OK*
Sitaatit tarkistettu 14.12..08

[Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study.](#)

Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO 3rd, Li J, Louie J, Furst DE.

Arthritis Rheum. 2008 Jul;58(7):1921-30. OK

PMID: 18576334 [PubMed - indexed for MEDLINE] Otettu M 12.11.09

[Related Articles](#) [Free article at journal site](#)

[Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and long-standing rheumatoid arthritis.](#)

Weinblatt ME, Bathon JM, Kremer JM, Fleischmann RM, Schiff MH, Martin RW, Baumgartner SW, Park GS, Mancini EL, Genovese MC.

Arthritis Care Res (Hoboken). 2010 Oct 18. [Epub ahead of print]

PMID: 20957659 [PubMed - as supplied by publisher] Otettu 13.10.12 [Ei oteta](#)

[Related citations](#)

[Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial.](#)

Weinblatt ME, Bingham CO 3rd, Mendelsohn AM, Kim L, Mack M, Lu J, Baker D, Westhovens R.

Ann Rheum Dis. 2012 Jun 1. [Epub ahead of print]

PMID:

22661646 Otettu 20.10.12 [Ei oteta](#)

[PubMed - as supplied by publisher]

[Free Article](#)

[Related citations](#)

[Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.](#)

Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, Maldonado M, Fleischmann R.

Arthritis Rheum. 2013 Jan;65(1):28-38. doi: 10.1002/art.37711.

PMID:

23169319 Otettu 28.10.16

[PubMed - indexed for MEDLINE]

[Free PMC Article](#)

[Related citations](#)

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. *Clin Ther.* 2003;25:1700–21. doi: 10.1016/S0149-2918(03)80164-9. [\[PubMed\]](#)

Otettu M 12.11.09 **Ei oteta**

Weisman MH, Paulus HE, Burch FX, Kivitz AJ, Fierer J, Dunn M, et al. A placebo controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases.

Rheumatology (Oxford) 2007;46:1122–5 Otettu M 12.11.09 Ei löydy

Weiss JE, Eberhard BA, Chowdhury D, et al. Infliximab as a novel therapy for refractory Kawasaki disease. *J Rheumatol.* 2004;31:808 – 810. Otettu 13.10.12 **OK**

Good correlation between changes in objective and subjective signs of inflammation in short- but not long-diseased patients with axial spondyloarthritis treated with tumor necrosis factor-blockers.

Weiβ A, Song IH, Haibel H, Listing J, Sieper J.

Arthritis Res Ther. 2014 Jan 30;16(1):R35. [Epub ahead of print]

PMID:

24476416

[PubMed - as supplied by publisher] Otettu
28.10.16

Free PMC Article

Related citations

256.

Good correlation between changes in objective and subjective signs of inflammation in short- but not

long-diseased patients with axial spondyloarthritis treated with tumor necrosis factor-blockers.

Weiβ A, Song IH, Haibel H, Listing J, Sieper J.

Arthritis Res Ther. 2014 Jan 30;16(1):R35. [Epub ahead of print]

PMID:

24476416

[PubMed - as supplied by publisher] Katso

[Free PMC Article](#)

[Related citations](#)

Efficacy of etanercept for the treatment of psoriasis: an overview of the Italian clinical experience from the real-life setting and independent studies.

Vena GA, Cassano N, Piaserico S, Conti A, Girolomoni G.

Immunopharmacol Immunotoxicol. 2012 Jun 11. [Epub ahead of print]

PMID:22686544

[PubMed - as supplied by publisher] Ei oteta

[Related citations](#)

Wendling D, Materne GE, Michel F, Lohse A,
Lehuede G, Toussitot E,
et al. Infliximab continuation rate in patients with
rheumatoid arthritis
in everyday practice. Joint Bone Spine
2005;72:628-31 Otettu 13.10.12 Ei oteta

Wendling D, Auge B, Bettinger D et al
Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during
infliximab treatment for severe spondyloarthropathy
Ann Rheum Dis 2005; 64: 788 - 9. Kokotekstinä OK*
Ref. tarkistettu 29.4.08

Wendling D, Murad M, Mathieu S, Berger E, Rumbach L.
Systemic nocardiosis in a case of rheumatoid arthritis treated
with tumor necrosis factor blockers.
J Rheumatol 2008;35:539—42. Otettu 20.10.12 OK

Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFalpha antagonist therapy.

Wendling D, Cedo JP, Racadot E.

Joint Bone Spine. 2008 Oct;75(5):559-62. Otettu m 12.11.09 Ei oteta

PMID: 18674944 [PubMed - indexed for MEDLINE]

Related Articles

New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases.

Wendling D, Paccou J, Berthelot JM, Flipo RM, Guillaume-Czitrom S, Prati C, Dernis E, Direz G, Ferrazzi V, Ristori JM; CRI.

Semin Arthritis Rheum. 2011 Dec;41(3):503-10. Epub 2011 Aug 20.

PMID:

Otettu 13.10.12 Ei oteta

21862108

[PubMed - indexed for MEDLINE]

Related citations

Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease.

Wendling D, Streit G, Toussirot E, Prati C.

Joint Bone Spine. 2008 Oct;75(5):540-3. Epub 2008 Jul 31.

PMID: 18674945 [PubMed - indexed for MEDLINE] Otettu m 12.11.09

9 OK

Related Articles

[Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy.](#)

Wendling D, Di Martino V, Prati C, Toussirot E, Herbein G.

Joint Bone Spine. 2009 May;76(3):308-11. Epub 2009 Apr 5.

PMID: 19346146 [PubMed - indexed for MEDLINE] Otettu M 12.11.09

[Related Articles](#) [OK](#)

[Comparing the risk of developing uveitis in patients initiating anti-TNF therapy for ankylosing spondylitis: An analysis of a large US claims database.](#)

Wendling D, Joshi A, Reilly P, Jalundhwala YJ, Mittal M, Bao Y.

Curr Med Res Opin. 2014 Sep 25:1-28. [Epub ahead of print]

PMID:

25252590

[PubMed - as supplied by publisher] ei ole M

[Related citations](#)

Venetsanopoulou AI, Voulgari PV, Alamanos Y,
Papadopoulos CG, Markatseli TE, Drosos AA(2007) Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis. Rheumatol Int 27: 935–939

Otettu M 12.11.09 [OK](#)

[Efficacy of biologicals in the treatment of rheumatoid arthritis. a meta-analysis.](#)

Venkateshan SP, Sidhu S, Malhotra S, Pandhi P.

Pharmacology. 2009;83(1):1-9. Epub 2008 Oct 28. Review.

PMID: 18957873 [PubMed - indexed for MEDLINE] [ei oteta](#)

[Related Articles](#)

[Efficacy and safety of etanercept in patients with psoriasis and hepatitis C.](#)

Ventura F, Gomes J, Duarte Mda L, Fernandes JC, Brito C.

Eur J Dermatol. 2010 Nov-Dec;20(6):808-9. Epub 2010 Oct 5. No abstract available.

PMID: 20923749 [PubMed - indexed for MEDLINE] [ei ole M](#)

[Related citations](#)

A Randomized, Double-blind, Placebo-controlled Study of Tumor Necrosis Factor- α Blockade in Severe Persistent Asthma

Wenzel et al.

Am. J. Respir. Crit. Care Med. 2009;179:549-558. Otettu m12.11.09

[ABSTRACT](#) | [FULL TEXT](#) [OK](#)

[Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification.](#)

Verbruggen G, Wittoek R, Vander Cruyssen B, Elewaut D.

Ann Rheum Dis. 2012 Jun;71(6):891-8. Epub 2011 Nov 29. [OK](#) [Kokotekstinä](#)

PMID:

22128078

[PubMed - indexed for MEDLINE]

[Free PMC Article](#)

[Related citations](#)

Verea, M. M, Del Pozo, J., Yebra-Pimentel, M T., Porta, A., Fonseca, E. (2004).

Psoriasisiform Eruption Induced by Infliximab. Ann Pharmacother 38: 54-57 Otettu M

12.11.09 [Ei oteta](#)

[\[Abstract\]](#) [\[Full Text\]](#)

Gabor Veres, Robert N Baldassano, Petar Mamula. (2007) Infliximab Therapy in Children and Adolescents with Inflammatory Bowel Disease. *Drugs* 67:12, 1703

[Ei löydy M](#)

[CrossRef](#)

Vergara G, Silvestre JF, Betlloch I, Vela P, Albares MP, Pascual JC. Cutaneous drug eruptions to infliximab: report of 4 cases with an interface dermatitis pattern [letter]. Arch Dermatol 2002; 138: 1258-9. Otettu M 12.11.09 [Ei oteta](#)

[Links](#)

Y. Bravo Vergel, N. S. Hawkins, K. Claxton, C. Asseburg, S. Palmer, N. Woolacott, I. N. Bruce, and M. J. Sculpher

The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis

Rheumatology, November 1, 2007; 46(11): 1729 - 1735. Otettu M 12.11.0

9 [Ei oteta](#)

[\[Abstract\]](#) [\[Full Text\]](#) [\[PDF\]](#)

[Histoplasmosis complicating tumor necrosis factor- \$\alpha\$ blocker therapy: a retrospective analysis of 98 cases.](#)

Vergidis P, Avery RK, Wheat LJ, Dotson JL, Assi MA, Antoun SA, Hamoud KA, Burdette SD, Freifeld AG, McKinsey DS, Money ME, Myint T, Andes DR, Hoey CA, Kaul DA, Dickter JK, Liebers DE, Miller RA, Muth WE, Prakash V, Steiner FT, Walker RC, Hage CA.

Clin Infect Dis. 2015 Aug 1;61(3):409-17. doi: 10.1093/cid/civ299.

PMID:

25870331 Otettu 28.10.16

[Free PMC Article](#)

[Similar articles](#)

[Pharmacodynamics of TNF- \$\alpha\$ inhibitors in psoriasis.](#)

Vergou T, Moustou AE, Sfikakis PP, Antoniou C, Stratigos AJ.

Expert Rev Clin Pharmacol. 2011 Jul;4(4):515-23. Otettu 13.10.12 [Ei oteta](#)

PMID:

22114860

[PubMed - in process]

[Related citations](#)

[Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B.](#)

Verhelst X, Orlent H, Colle I, Geerts A, De Vos M, Van Vlierberghe H.

Eur J Gastroenterol Hepatol. 2010 Apr;22(4):494-9. Review.

Otettu 13.10.12 [OK](#)

[Aortitis during etanercept therapy for ankylosing spondylitis: Finding the culprit.](#)

Verhoeven F, Bossert M, Lohse-Walliser A, Balblanc JC.
Joint Bone Spine. 2012 May 8. [Epub ahead of print] No abstract available.
PMID:

Otettu 20.10.12 **OK**

22575065

[PubMed - as supplied by publisher]

[Related citations](#)

[Adalimumab for orbital myositis in a patient with Crohn's disease who discontinued infliximab: a case report and review of the literature.](#)

Verma S, Kroeker KI, Fedorak RN.
BMC Gastroenterol. 2013 Apr 4;13:59. doi: 10.1186/1471-230X-13-59.

PMID:

23556424 [Kokotekstinä](#)

[PubMed - in process]

[Free PMC Article](#)

[Related citations](#)

VERMEIRE, S., M. NOMAN, G. VAN ASSCHE, et al. 2003. Autoimmunity associated with anti-tumor necrosis factor a treatment in Crohn's disease: a prospective cohort study.

Gastroenterology 125: 32–39. Otettu M 12.11.09

Vermeire S, Noman M, Van Assche G et al

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

Gut 2007;56: 1226-31 Otettu M 12.11.09

- [\[Abstract\]](#) [\[Full Text\]](#)

Severine Vermeire, M.D., Ph.D., Edouard Louis, M.D., Ph.D., An Carbonez, Ph.D., Gert Van Assche, M.D., Ph.D., Maja Noman, M.D., Jacques Belaiche, M.D., Ph.D., Martine De Vos, M.D., Ph.D., Andre Van Gossum, M.D., Ph.D., Paul Pescatore, M.D., Rene Fiasse, M.D., Ph.D., Paul Pelckmans, M.D., Ph.D., Hendrik Reynaert, M.D., Geert D'Haens, M.D., Ph.D., and Paul Rutgeerts, M.D., Ph.D., F.R.C.P., Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. (2002) Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.

The American Journal of Gastroenterology 2357-2363 Otettu M 12.11.09

Vermeire S, Noman M, van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor treatment in Crohn's disease: a prospective cohort study.

Gastroenterology 2003;125:32-39

Otettu M 12.11.09

[\[ISI\]](#)[\[Medline\]](#)

Generalized interstitial granuloma annulare--response to adalimumab.

Werchau S, Enk A, Hartmann M.

Int J Dermatol. 2010 Apr;49(4):457-60. Otettu 13.10.12 Ei oteta

PMID: 20465706 [PubMed - indexed for MEDLINE][\[Related citations\]](#)

TNF α inhibitors restrict T cell activation and cycling via Notch-1 signalling in inflammatory bowel disease.

Werner L, Berndt U, Paclik D, Danese S, Schirbel A, Sturm A.
Gut. 2012 Jul;61(7):1016-27. Epub 2011 Nov 7. Otettu 18.6.18
PMID:

22068169

[PubMed - in process]

[Related citations](#)

350.

718.

Resolution of adalimumab-induced psoriasis after vitamin D deficiency treatment.

Werner de Castro GR, Neves FS, Pereira IA, Fialho SC, Ribeiro G, Zimmermann AF.
Rheumatol Int. 2012 May;32(5):1313-6. Epub 2011 Feb 3.
PMID:

21290129 Otettu 13.10.12

[PubMed - in process]

[Related citations](#)

The impact of PEGylation on biological therapies.

Veronese FM, Mero A.

BioDrugs. 2008;22(5):315-29. Review. Otettu 20.10.12

PMID:

18778113

[PubMed - indexed for MEDLINE]

[Related citations](#)

Verschueren K, Van Essche E, Verschueren P, Taelman V, Westhovens R. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. *Clin Rheumatol* 2007;26:1969–71. Otettu M 12.11.09

Verstappen SM, Jacobs JW, Hyrich KL
Effect of anti-tumor necrosis factor on work disability.
J Rheumatol 2007;34:2126–8. **ei oteta**

[Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register.](#)

Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL; BSRBR Control Centre Consortium, BSR Biologics Register. [Kokotekstinä](#)
Ann Rheum Dis. 2011 May;70(5):823–6. Epub 2011 Feb 28.
PMID:

21362710 Otettu 28.10.16

[PubMed - indexed for MEDLINE]

[**Free PMC Article**](#)

[Related citations](#)

Vesga L, Terdiman J P, Mahadevan
Adalimumab use in pregnancy.

Gut 2005;54: 890-890 [Kokoteksinä](#) **OK***

Ref. tarkistettu 29.4.2008

Adalimumab-associated bullous pemphigoid in a patient with ulcerative colitis.

Wessman LL, Blixt EK, Wetter DA, Miest RY.

JAAD Case Rep. 2017 Jul 19;3(4):339-341. doi: 10.1016/j.jdcr.2017.03.008. eCollection 2017 Jul. No abstract available.

PMID:

28752126 Ota kotona

[Free PMC Article](#)

[Similar articles](#)

Transient blood eosinophilia during treatment with Adalimumab.

Vester K, Rüger RD, Harth W, Simon JC.

J Eur Acad Dermatol Venereol. 2012 Jul;26(7):924-5. doi: 10.1111/j.1468-3083.2011.04169.x. Epub 2011 Jul 1. No abstract available. Otettu 13.10.12 [Ei oteta](#)

PMID:

21718365

[PubMed - in process]

[Related citations](#)

804.

[Submandibular Sialoadenitis in an Infant Exposed to Adalimumab and Infliximab in Utero.](#)

Vestergaard T, Brock B, Christensen LA, Julsgaard M.

J Crohns Colitis. 2017 Oct 1;11(10):1284-1285. doi: 10.1093/ecco-jcc/jx045. No abstract available.

PMID:

28369262 Ota v. 2019

[Similar articles](#)

Westhovens R, Yocum D, Han J et al

The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial.

Arthritis Rheum 2006; **54**: 1075–86. Otettu 13.10.12 Ei oteta

[\[CrossRef\]](#)[\[Medline\]](#)

[Cutaneous lupus erythematosus induced by adalimumab.](#)

Vezzoli P, Violetti SA, Serini SM, Muratori S, Berti E, Crosti C.

J Dermatol. 2011 Mar;38(3):283-4. doi: 10.1111/j.1346-8138.2010.00951.x. Epub 2010 Sep 29. No abstract available.

PMID:

Otettu 20.10.12 OK

21342233

[PubMed - indexed for MEDLINE]

[Related citations](#)

White ES

Infliximab in sarcoidosis: more answers or more questions?

Am. J. Respir. Crit. Care Med. 2006; 174: 732 - 733. [Kokotekstinä](#)

Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD. In vivo neutralization of TNF promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 2001;167:6821–6 . [Ei oteta](#)

[Otettu M 12.11.09](#)

[\[Abstract/Free Full Text\]](#)

E. F. Vicente, A. Hernandez-Nunez, J. Aspa, M. Aragues, and R. Garcia-Vicuna

Crohn's disease, relapsing polychondritis and epidermolysis bullosa acquisita: an immune-mediated inflammatory syndrome

Rheumatology, January 31, 2008; (2008) kem330v1. Otettu M 12.11.09

[\[Full Text\]](#) [\[PDF\]](#)

Wick MC, Ernestam S, Lindblad S, Bratt J,
Klareskog L, van Vollen-
hoven RF.

Adalimumab restores clinical response in patients
with secondary failure to infliximab or etanercept:
results from the STURE reg-istry at Karolinska
University Hospital.

Arthritis Rheum 2004;50:S393– 4.ei löydy eikä oteta

Wick MC, Ernestam S, Lindblad S et al

Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.

Scand J Rheumatol 2005; 34:353–8. Otettu M 12.11.0 9 **Ei oteta**

[\[CrossRef\]](#) [\[ISI\]](#) [\[Medline\]](#)

Victor FC, Gottlieb AB, Menter A. Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis.

Clin Dermatol 2003; 21:392–7. ei oteta

Vidal F, Fontova R, Richart C. (2003). Severe Neutropenia and Thrombocytopenia Associated with Infliximab. Ann Intern Med 2003; 139: W-63-W-63 Kokotekstinä * E 238

[Crohn's disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature.](#)

Wiegering V, Morbach H, Dick A, Girschick HJ.

Rheumatol Int. 2010 Apr;30(6):801-4. Epub 2009 Jun 9. Review.Otetu M 12.11.0 **Ei oteta**

MPMID: 19506877 [PubMed - indexed for MEDLINE][Related citations](#)

[Development of exclusively cutaneous sarcoidosis in patient with rheumatoid arthritis during treatment with etanercept.](#)

Vieira MA, Saraiva MI, Silva LK, Fraga RC, Kakizaki P, Valente NY.

Rev Assoc Med Bras (1992). 2016 Nov;62(8):718-720. doi: 10.1590/1806-9282.62.08.718.

PMID:

27992009 Ota kotona

[**Free Article**](#)

[Similar articles](#)

[A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis.](#)

Wiens A, Correr CJ, Pontarolo R, Venson R, Quinalha JV, Otuki MF. Scand J Immunol. 2009 Oct;70(4):337-44.

PMID: 19751268 [PubMed - in process] [Kokotekstinä](#)

[Related Articles](#)

[Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis.](#)

Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R. Pharmacotherapy. 2010 Apr;30(4):339-53. Review.

Otettu 13.10.12 **Ei oteta**

PMID: 20334454 [PubMed - indexed for MEDLINE][Related citations](#)

[A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis.](#)

Wiens A, Correr CJ, Venson R, Otuki MF, Pontarolo R.

Rheumatol Int. 2010 Jun;30(8):1063-70. Epub 2009 Aug 26. Review.

Otettu 20.10.12 **ei oteta**

PMID: 19707765 [PubMed - indexed for MEDLINE][Related citations](#)

C A Wijbrandts, M G W Dijkgraaf, M C Kraan, M Vinkenoog, T J Smeets, H Dinant, K Vos, W F Lems, G J Wolbink, D Sijpkens, *et al.*

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor {alpha} expression in the synovium

Ann Rheum Dis, August 1, 2008; 67(8): 1139 - 1144. Otettu m 12.11.09

[\[Abstract\]](#) [\[Full Text\]](#) [\[PDF\]](#) **OK**

[Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss.](#)

Wijbrandts CA, Klaasen R, Dijkgraaf MG, Gerlag DM, van Eck-Smit BL, Tak PP.

Ann Rheum Dis. 2009 Mar;68(3):373-6. [Kokotekstinä](#)

Epub 2008 Apr 13. PMID: 18408246 [PubMed - indexed for MEDLINE][Free PMC Article](#)[Free text](#)[Related citations](#)

Use of antirheumatic drugs in mothers and fathers before and during pregnancy-a population-based cohort study.

Viktil KK, Engeland A, Furu K.

Pharmacoepidemiol Drug Saf. 2009 Aug;18(8):737-42. ei ole M netissä

PMID: 19504626 [PubMed - in process] Otettu M 12.11.09

[Related Articles](#)

Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers.

Viktil KK, Engeland A, Furu K.

Scand J Rheumatol. 2012 May;41(3):196-201. Epub 2012 Mar 9. Otettu 18.6.18

PMID:

22401133

[PubMed - indexed for MEDLINE]

[Related citations](#)

Wiland P, Glowska A, Chlebicki A, Szechinski J. Analysis of efficacy and safety of multiple intravenous infusion of anti-tumor necrosis factor-alpha monoclonal antibody (Remicade) combined with methotrexate compared with sodium aurothiomalate and intramuscular depot methylprednisolone in rheumatoid arthritis. Pol Arch Med Wewn. 2002;108:1055-63. [[PubMed](#)]

ei ole M netissä

SAPHO syndrome with unusual cutaneous manifestations treated successfully with etanercept.

Vilar-Alejo J, Dehesa L, de la Rosa-del Rey P, Novoa-Medina J, Valerón Almazán P, Santana Medina N, Bastida J.

Acta Derm Venereol. 2010 Sep;90(5):531-2 [Kokotekstina](#)

. No abstract available.

PMID: 20814638 [PubMed - indexed for MEDLINE] **Free Article**

[Related citations](#)

[Reversible male infertility under treatment with an anti-TNF \$\alpha\$ agent: a case report.](#)

Wildi LM, Haraoui B.

Ann Rheum Dis. 2012 Mar;71(3):473-4. Epub 2011 Dec 2. No abstract available.

Otettu 18.6.18

PMID:

22138196

[PubMed - indexed for MEDLINE]

[Related citations](#)

Wilkinson N, Jackson G, Gardner-Medwin J

Biologic therapies for juvenile arthritis

Arch. Dis. Child. 2003; 88(3): 186 - 91. [Kokotekstina](#)

Wilkinson NMR, Erendzhinova E, Zeft A et al

Infliximab as rescue therapy in three cases of paediatric Wegener's granulomatosis

Rheumatology 2006; 45: 1047 - 8. Otettu M 12.11.09

[\[Full Text\]](#) [\[PDF\]](#)

Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis.

William M, Faez S, Papaliodis GN, Lobo AM.

J Ophthalmic Inflamm Infect. 2012 May 14. [Epub ahead of print] No abstract available.

PMID:

22581347 Otettu 20.10.12 Ei oteta

[PubMed - as supplied by publisher]

[Related citations](#)

Williams RO, Feldmann M, Maini RN.

Anti-tumor necrosis factor ameliorates joint disease in murine collagen -induced arthritis.

Proc Natl Acad Sci USA 1992;89:9784-9788

[Kokotekstinä](#)

Williams RO, Feldmann M, Maini RN. Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor. Ann Rheum Dis 2000;59(Suppl 1):75-80

[Kokotekstinä](#)

[Williams RO](#), Mason LJ, Feldmann M, Maini RN. Synergy between anti-CD4 and anti-tumour necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994; 91: 2762-66 [Kokotekstinä](#)

[TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.](#)

Williams VL, Cohen PR. Otettu 18.6.18

Int J Dermatol. 2011 May;50(5):619-25. doi: 10.1111/j.1365-4632.2011.04871.x.

PMID:

21506984

[PubMed - in process]

[Related citations](#)

269.

[Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor- \$\alpha\$ therapy in inflammatory bowel disease.](#)

Williams CJ, Peyrin-Biroulet L, Ford AC.

Aliment Pharmacol Ther. 2014 Mar;39(5):447-58. doi: 10.1111/apt.12624. Epub 2014 Jan 20.

PMID:

24444171

[PubMed - in process] Otettu 18.6.18

[Related citations](#)

[Subcutaneous Injection of Adalimumab Trial compared with Control \(SCIATiC\): a randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica.](#)

Williams NH, Jenkins A, Goulden N, Hoare Z, Hughes DA, Wood E, Foster NE, Walsh DA, Carnes D, Sparkes V, Hay EM, Isaacs J, Konstantinou K, Morrissey D, Karppinen J, Genevay S, Wilkinson C.

Health Technol Assess. 2017 Oct;21(60):1-180. doi: 10.3310/hta21600.

PMID:

29063827 Ota kotona

[Free Article](#)

[Similar articles](#)

[Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis.](#)

Villiger PM, Caliezi G, Cottin V, Förger F, Senn A, Østensen M.

Ann Rheum Dis. 2010 Oct;69(10):1842-4. Epub 2010 Jul 7. Otettu 20.10.12

PMID: 20610443 [PubMed - indexed for MEDLINE][Related citations](#)

Willot S, Vermeire S, Ohresser M, et al.
No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease. Pharmacogenet Genomics 2006; 16: 37-42. Otettu M 12.11.09

235.

[Listeria monocytogenes infection in Crohn's disease treated with adalimumab.](#)

Willson KJ, Jacob A, Shetti MP, Bhatia R, Yee K, Osler W.

Med J Aust. 2012 Oct 15;197(8):466-7. No abstract available.

PMID:

23072245 ei ole M

[PubMed - indexed for MEDLINE]

[Related citations](#)

[**Etanercept-induced generalization of chronic, localized, anogenital bullous pemphigoid in a psoriatic patient.**](#)

Wilmer EN, Becker N, Chen A, Kroumpouzos G.

JAAD Case Rep. 2016 Jan 22;2(1):25-7. doi:

10.1016/j.jdcr.2015.12.006. eCollection 2016 Jan. No abstract available.

PMID:

27051819 Otettu 28.10.16

[Free PMC Article](#)

[Similar articles](#)

Wilson MW, Sherry WJ, Haik BG. Infliximab in the treatment of recalcitrant idiopathic orbital inflammation. Ophthal Plast Reconstr Surg 2004;20:381-3. Otettu M 12.11.09

[Tumor necrosis factor alpha and colitis-associated colon cancer.](#)

Wilson JA.

N Engl J Med. 2008 Jun 19;358(25):2733-4. No abstract available. Erratum in:

N Engl J Med. 2008 Dec 25;359(26):2853.

PMID: 18565868 [PubMed - indexed for MEDLINE] [ei oteta](#)

Related Articles

595.

Treatment of refractory chronic urticaria with tumor necrosis factor-alfa inhibitors.

Wilson LH, Eliason MJ, Leiferman KM, Hull CM, Powell DL.

J Am Acad Dermatol. 2011 Jun;64(6):1221-2. No abstract available.

PMID:

Otettu 18.6.18

21571206

[PubMed - indexed for MEDLINE]

Related citations

Winfield et al.

Eosinophilic cellulitislike reaction to subcutaneous etanercept injection.

Arch Dermatol 2006;142:218-220. Kokotekstinä OK*

Birth defect rates in women using Adalimumab (Humira®) to treat immunologic-based infertility in IVF patients.

Winger EE, Reed JL, Ashoush S, El-Toukhy T, Ahuja S, Tarani M.

Am J Reprod Immunol. 2011 Sep;66(3):237-41. doi: 10.1111/j.1600-0897.2011.00994.x. Epub 2011 Apr 19.

PMID:

Otettu 20.10.12 OK

21501282

[PubMed - indexed for MEDLINE]

[Related citations](#)

744.

Degree of TNF- α /IL-10 cytokine elevation correlates with IVF success rates in women undergoing treatment with Adalimumab (Humira) and IVIG.

Winger EE, Reed JL, Ashoush S, El-Toukhy T, Ahuja S, Taranissi M.

Am J Reprod Immunol. 2011 Jun;65(6):610-8. doi: 10.1111/j.1600-0897.2010.00946.x. Epub 2011 Jan 12.

PMID:

Otettu 18.6.18

21223418

[PubMed - indexed for MEDLINE]

[Related citations](#)

Sustained remission after long-term biological therapy in patients with large vessel vasculitis: an analysis of ten cases.

Vinicki JP, García-Vicuña R, Arredondo M,
López-Bote JP, García-Vadillo JA, Castañeda S,
Álvaro-Gracia JM.

Reumatol Clin. 2016 Aug 4. pii:

S1699-258X(16)30063-8. doi:
10.1016/j.reuma.2016.06.003. [Epub ahead of
print] English, Spanish.

PMID:

27499427 Otettu 28.10.16

[Free Article](#)

[Similar articles](#)

[\[A case of granulomatous rosacea coinciding with the use of etanercept: no
relapse with infliximab\]](#)

[Intravenous CDP870, a PEGylated Fab' fragment of a humanized
antitumour necrosis factor antibody, in patients with moderate-to-severe
Crohn's disease: an exploratory study.](#)

Winter TA, Wright J, Ghosh S, Jahnsen J, Innes A, Round P.

Aliment Pharmacol Ther. 2004 Dec;20(11-12):1337-46. Otettu 20.10.12 **Ei oteta**

PMID:

15606396

[PubMed - indexed for MEDLINE]

Free Article

[Related citations](#)

Winter UM, Treudler R, Paasch U, Sticherling M, Simon JC.

Hautarzt. 2008 Sep;59(9):724-7. German.

PMID: 18465064 [PubMed - indexed for MEDLINE] Otettu mm 12.11.09

[Related Articles](#)

Keystone E, et al. A comparison of etanercept and methotrexate in

Winthrop K, Siegel J. Tuberculosis cases associated with inflix-imab and etanercept. Clin Infect Dis 2004;39:1256-7. ei oteta

[Winthrop KL](#), Siegel JN, Jereb J, ym. Tuberculosis associated with therapy against tumor necrosis factor alfa. Arthr Rheum 2005;52:2968-74. [Kokotekstinä](#) *

Winthrop, K L

Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor {alpha}.

Ann Rheum Dis 2005; 64: iv29-iv30 [Kokotekstinä](#)

Winthrop, K.L. 2006. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. *Nat. Clin. Pract. Rheumatol.* 2:602–610. [\[CrossRef\]](#) [\[Medline\]](#) ei ole M

K L Winthrop

Serious infections with antirheumatic therapy: are biologicals worse?

Ann Rheum Dis, November 1, 2006; 65(suppl_3): iii54 - iii57. Otettu 20.10.12

[\[Abstract\]](#) [\[Full Text\]](#) [\[PDF\]](#)

149.

Mycobacterial diseases and antitumour necrosis factor therapy in USA.

Winthrop K, Baxter R, Liu L, Varley C, Curtis J, Baddley J, McFarland B, Austin D, Radcliffe L, Suhler E, Choi D, Rosenbaum J, Herrinton L.

Ann Rheum Dis. 2012 Apr 20. [Epub ahead of print] Otettu 18.6.18

PMID:

22523429

[PubMed - as supplied by publisher]

[Related citations](#)

282.

Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study.

Winthrop KL, Chen L, Fraunfelder FW, Ku JH, Varley CD, Suhler E, Hills WL, Gattey D, Baddley

JW, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Herrinton LJ, Fraunfelder FT, Saag KG, Lewis JD, Solomon DH, Curtis JR.

Am J Ophthalmol. 2013 Jan;155(1):183-189.e1. doi: 10.1016/j.ajo.2012.06.023. Epub 2012 Sep 8.

PMID:

22967869 Otettu 18.6.18

[PubMed - indexed for MEDLINE]

[Related citations](#)

[Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease.](#)

Viola F, Civitelli F, Di Nardo G, Barbato MB, Borrelli O, Oliva S, Conte F, Cucchiara S.

Am J Gastroenterol. 2009 Oct;104(10):2566-71. Epub 2009 Jun 23.

Otettu 20.10.12 OK

PMID: 19550415 [PubMed - indexed for MEDLINE][Related citations](#)

[Possible association of etanercept, venous thrombosis, and induction of antiphospholipid syndrome.](#)

Virupannavar S, Brandau A, Guggenheim C, Laird-Fick H.

Case Rep Rheumatol. 2014;2014:801072. doi: 10.1155/2014/801072. Epub 2014 May 15.

PMID:

24949211 Katso

[PubMed]

[Free PMC Article](#)

[Related citations](#)

Identification of Pneumocystis colonization in patients treated with Infliximab
Wissmann G, et al.

Ann Rheum Dis Online, 4 Feb 2008 [Kokotekstina](#) **OK***

Vis M, Nurmohamed MT, Wolbink G et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis.m
J Rheumatol 2005; 32:252-5. Otettu 18.6.18

Vis M, Havaardsholm EA, Haugeberg G, Uhlig T,
Voskuyl AE, van de Stadt RJ, et al. Evaluation of bone
mineral density, bone metabolism, osteoprotegerin and recep-
tor activator of the NFkappaB ligand serum levels during
treatment with infliximab in patients with rheumatoid
arthritis. Ann Rheum Dis 2006;65:1495-9. Otettu 18.6.18

351.

[Rheumatic diseases should be actively treated in](#)

[pregnancy, new guidelines say.](#)

Wise J.

BMJ. 2016 Jan 18;532:i312. doi:
10.1136/bmj.i312. No abstract available.

PMID:

26787749 Otettu 18.6.18

[Similar articles](#)

VISVANATHAN, S., C. WAGNER, J. SMOLEN, et al. 2006. IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Arthritis Rheum. 54: 2840–2844. Otettu M 12.11.09

VisvanathanS, KeenanGF, Baker DG, et al.
Response to pneumococcal
vaccine in patients with early rheumatoid arthritis

receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol 2007; 34:952–957 Otettu 18.6.18

[E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.](#)

Visvanathan S, Wagner C, Rojas J, Kay J, Dasgupta B, Matteson EL, Mack M, Baker DG, Rahman MU.

J Rheumatol. 2009 Jul;36(7):1371-9. Epub 2009 Jun 1. Erratum in: J Rheumatol. 2011 Jan;38(1):183. Otettu 18.6.18

PMID:

19487269

[PubMed - indexed for MEDLINE]

[Related citations](#)

[Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study.](#)

Visvanathan S, Rahman MU, Keystone E, Genovese M, Klareskog L, Hsia E, Mack M, Buchanan J, Elashoff M, Wagner C.

Arthritis Res Ther. 2010;12(6):R211. Epub 2010 Nov 17. Ota kotona

PMID:

21083889

[PubMed - in process]

Free PMC Article

[Free full text](#) [Related citations](#)

[Left ventricular function in rheumatoid arthritis during anti-TNF- \$\alpha\$ treatment: a speckle tracking prospective echocardiographic study.](#)

Vizzardi E, Cavazzana I, Franceschini F, Bonadei I, Sciatti E, Lombardi CM, Tincani A, Metra M.

Monaldi Arch Chest Dis. 2016 Jun 22;84(1-2):716.
doi: 10.4081/monaldi.2015.716.

PMID:

27374036 Ota kotona

[Free Article](#)

[Similar articles](#)

Orbital Sarcoid-Like Granulomatosis After
Inhibition of Tumor Necrosis Factor- α

Wladis EJ, Tarasen AJ, Roth ZJ, Farber MG, Ross J, Michaels VM.

Ophthal Plast Reconstr Surg. 2014 May 19. [Epub ahead of print]

PMID:

24841734

[PubMed - as supplied by publisher] Otettu 18.6.18

Related citations

[The Impact of Inadequate Temperature Storage Conditions on Aggregate and Particle Formation in Drugs Containing Tumor Necrosis Factor-Alpha Inhibitors.](#)

Vlieland ND, Nejadnik MR, Gardarsdottir H, Romeijn S, Sediq AS, Bouvy ML, Egberts ACG, van den Bemt BJF, Jiskoot W.

Pharm Res. 2018 Feb 5;35(2):42. doi: 10.1007/s11095-017-2341-x.

PMID:

29404710 Ota kotona

[Free PMC Article](#)

[Similar articles](#)

[Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up.](#)

Vogelzang EH, Kneepkens EL, Nurmohamed MT,

van Kuijk AW, Rispens T, Wolbink G, Krieckaert CL.

Ann Rheum Dis. 2014 Aug 12. pii:
annrheumdis-2014-205554. doi:
10.1136/annrheumdis-2014-205554. [Epub ahead
of print]

PMID:

25115447

[PubMed - as supplied by publisher] Otettu 18.6.18

Related citations

Voigtlander, C., Luftl, M., Schuler, G., Hertl, M. (2001). Infliximab (Anti-Tumor Necrosis Factor {alpha} Antibody): A Novel, Highly Effective Treatment of Recalcitrant Subcorneal Pustular Dermatosis (Sneddon-Wilkinson Disease). *Arch Dermatol* 137: 1571-1574 Otettu M 12.11.09

- [\[Full Text\]](#)

117.

[Pemphigus vulgaris treated with adalimumab: case study.](#)

Vojáčková N, Fialová J, Vaňousová D, Hercogová J.

Dermatol Ther. 2012 Jan-Feb;25(1):95-7. doi: 10.1111/j.1529-8019.2012.01433.x.

Otettu 18.6.18

PMID:

22591504

[PubMed - in process]

[Related citations](#)

[\[Successful therapy of sacroiliitis in SAPHO syndrome by etanercept.\]](#)

Wolber C, David-Jelinek K, Udvardi A, Artacker G, Volc-Platzer B, Kurz H.

Wien Med Wochenschr. 2011 Jan 25. [Epub ahead of print] German.

PMID: 21253816 [PubMed - as supplied by publisher]

[Related citations](#)

Wolbink G J, Voskuyl A E, Lems W F et al

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.

Ann Rheum Dis 2005; 64: 704-7 [Kokotekstinä](#)

Sitaatit tarkistettu 30.4.08

Wolbink G J, Vis M, Lems W et al

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis.

Arthritis Rheum 2006;54:711–15. [Kokotekstinä](#) OK*

[Wolfe F](#), Michaud K, Dewitt EM. Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues. Ann Rheum Dis 2004; 63 Suppl 2: ii13-7. [Kokotekstinä](#) *

[Wolfe F](#), Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372-9. [Kokotekstinä](#) *

[Wolfe F](#) , Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 1740-51. [Kokotekstinä](#) *

[Wolfe F](#), Michaud K, Pincus T. Do rheumatology cost–effectiveness analyses make sense? Rheumatology 2004;43:4–6 [Kokotekstinä](#).

Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors and the effect of anti-tumor necrosis factor therapy. Am J Med 2004;116:305-11. Otettu M 12.11.09
[\[MEDLINE\]](#)

Wolfe F, Michaud K: Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: an investigation in 24,831 patients. J Rheumatol 2004, 31:2115-2120. ei oteta

Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med

2004; 116: 305 – 311.

Wolfe F, Caplan L, Michaud K.

Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia.

Associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.

Arthritis Rheum 2006; **54**: 628–34. Kokotekstinä OK*

Wolfe F, Allaire S, Michaud K. The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability.

J Rheumatol 2007;34:2211–17. Otettu 18.6.18

Wolfe F, Michaud K.

The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.

Arthritis Rheum 2007;56:1433–9. Otettu M 12.11.09

Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. *Rheum* 2007;56:1433–9. Otettu M 12.11.09

Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of

malignancy: analyses from a large US observational study. *Arthritis Rheum* 2007;56:2886–95. Otettu M 12.11.09

VOLL, R. E., KALDEN, J. R. (2005). Do We Need New Treatment That Goes beyond Tumor Necrosis Factor Blockers for Rheumatoid Arthritis?. *Annals NYAS Online* 1051: 799-810 Otettu M 12.11.09

- [\[Abstract\]](#) [\[Full Text\]](#)

WOLLINAU,KONRADH:Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis-alpha antibody. *J Eur Acad Dermatol Venereol* 2002; 16:127-9 Otettu 18.6.18

Volpe A, Caramaschi P, Carletto A, Pieropan S, Bambara LM, Biasi D. Psoriasis onset during infliximab treatment : description of two cases. *Rheumatol Int* 2006; 26: 1158-60. Otettu M 12.11.09

Von Andrian UH, Mackay CR. T-cell function and migration: two sides of the same coin. *N Engl J Med* 2000;343:1020–34. **Ei oteta**
[\[Free Full Text\]](#)

Wondergem MJ, Voskuyl AE, van Agtmael MA. A case of legionellosis during treatment with a TNFalpha antagonist. Scand J Infect Dis 2004;36:310-1. ei oteta

Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-8.
Otettu M 12.11.09

Dacryoadenitis, an extra-intestinal manifestation of Crohn's disease.

Wong JC, Rossman D, Bressler B.
Am J Gastroenterol. 2010 Aug;105(8):1904-6. No abstract available.
MPMID: 20686473 [PubMed - indexed for MEDLINE][Related citations](#)
Otettu 18.6.18

298.

Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies.

Wong AK, Kerkoutian S, Said J, Rashidi H, Pullarkat ST.
Clin Rheumatol. 2012 Apr;31(4):631-6. Epub 2011 Nov 18. Otettu 18.6.18
PMID:

22147207

[PubMed - indexed for MEDLINE]

[Related citations](#)

502.

[The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.](#)

[Wong DR, Pierik M, Seinen ML, van Bodegraven AA, Gilissen LP, Bus P, Bakker JA, Masclee AA, Neef C, Engels LG, Hooymans PM.](#)

[J Crohns Colitis. 2014 Feb;8\(2\):120-8. doi:](#)

[10.1016/j.crohns.2013.07.004. Epub 2013 Aug 7.](#)

[PMID:](#)

[23932783](#)

[\[PubMed - in process\] ei ole M](#)

[Related citations](#)

Vonkeman H E, Van Der Valk P D L P, Mulder L et al

Fatal extrapulmonary tuberculosis during treatment with the immunosuppressive infliximab.

Ned Tijdschr Geneeskd 2002;146:1196–9. [Ei ole M netissä](#)

[\[Medline\]](#)

Vonkeman H, ten Napel C, Rasker H, van de Laar M.

Disseminated primary varicella infection during infliximab treatment. J Rheumatol 2004; 31: 2517–2518.

Otettu 18.6.18

Woo JH, Lee HJ, Sung IH, Kim TH (2007) Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 34:1753–1759

Otettu 18.6.18

Wood KL, Hage CA, Knox KS, et al. (2003). Histoplasmosis after Treatment with Anti-Tumor Necrosis Factor- α Therapy.
Am J Respir Crit Care Med 2003;167: 1279-82 Kokotekstinä *
Sitaatit tarkistettu 15.1.08

Woolacott N, Hawkins N, Mason A et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006; 10:1-233, i-iv. **Ei oteta**

Wooley PH, Dutcher J, Widmer MB, ym. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993; 151:6602-7.
Otettu 18.6.18

Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.

Woolf RT, Smith CH, Robertson K, Barker JN.

Br J Dermatol. 2010 Oct;163(4):889-92. doi: 10.1111/j.1365-2133.2010.09893.x. Epub 2010 Jul 28. Review. No abstract available.

PMID: 20854408 [PubMed - in process]

Otettu 18.6.18

Related citations

Wooten M D, Reddy G V, Johnson R D. Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis. Del Med J 2000;72:517–19

ei ole M netissä

[\[Medline\]](#)

[Inclusion body myositis in a patient with long standing rheumatoid arthritis treated with anti-TNFalpha and rituximab.](#)

Vordenbäumen S, Neuen-Jacob E, Richter J, Schneider M.

Clin Rheumatol. 2010 May;29(5):555-8. Epub 2010 Jan 27.

PMID:

20108015

[PubMed - indexed for MEDLINE]

[Related citations](#)

419.

[Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro.](#)

Vos AC, Wildenberg ME, Arijs I, Duijvestein M, Verhaar AP, de Hertogh G, Vermeire S, Rutgeerts P, van den Brink GR, Hommes DW.

Inflamm Bowel Dis. 2012 Mar;18(3):401-8. doi: 10.1002/ibd.21818. Epub 2011 Sep 20.

Otettu 18.6.18

PMID:

21936028

[PubMed - indexed for MEDLINE]

[Related citations](#)

D. Vosse, R. Landewe, P. Garnero, D. van der Heijde, S. van der Linden, and P. Geusens

Association of markers of bone- and cartilage-degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis

Rheumatology, August 1, 2008; 47(8): 1219 - 1222. Otettu M 12.11.09

[\[Abstract\]](#) [\[Full Text\]](#) [\[PDF\]](#)

Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA. Infliximab therapy in established rheumatoid arthritis: an observational study. Am J Med

2005;118:515-2

Voulgari PV, Venetsanopoulou AI, Epagelis EK et al
Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year
experience
Ann Rheum Dis 2007; 66: 270 - 1. [Kokotekstinä](#) [OK*](#)

[Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.](#)

Voulgari PV.

Expert Rev Clin Immunol. 2010 Sep;6(5):721-33. Review.

PMID:

20828280

[PubMed - indexed for MEDLINE]

[Related citations](#)

[Adalimumab in the treatment of rheumatoid arthritis.](#)

Voulgari PV, Drosos AA.

Expert Opin Biol Ther. 2014 Mar 4. [Epub ahead of print]

PMID:

24588123

[PubMed - as supplied by publisher]

[Related citations](#) ei ole M

Wright RC. Atopic dermatitis-like eruption precipitated by infliximab.
J Am Acad Dermatol 2003; 49:160–1. Ei löydy M netistä

Wright SA, Taggart AJ

Pneumococcal vaccination for RA patients on TNF-{alpha} antagonists

Rheumatology 2004; 43: 523 - 523.

Ref. tarkistettu 10.2.08 [Kokotekstinä](#) OK*

[Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.](#)

Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M.

Curr Med Res Opin. 2008 Aug;24(8):2229-40. Epub 2008 Jun 23.

PMID: 18577308 [PubMed - indexed for MEDLINE] ei ole M netissä

[Related Articles](#)

VULTAGGIO A, MATUCCI A, PARRONCHI P,
ROSSI O, ROMAGNANI S, MAGGI E: Safety
and tolerability of infliximab therapy: sug-
gestions and criticisms based on wide clini-
cal experience. Int J Immunopathol Pharmacol 2008; 21: 367-74.

Ei ole M netissä

[Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population.](#)

Wu EQ, Feldman SR, Chen L, Kaltenboeck A, Yu AP, Gupta SR, Laitinen D, Willian MK.

Curr Med Res Opin. 2008 Dec;24(12):3493-501.

PMID: 19032131 [PubMed - indexed for MEDLINE] Ei ole M netissä
[Related Articles](#)

476.

[Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.](#)

Wu JJ, Poon KY, Bebchuk JD.

J Drugs Dermatol. 2013 Aug;12(8):899-903.

PMID:

23986163

[PubMed - indexed for MEDLINE] ei oteta

[Related citations](#)

222.

[Legionella pneumophila serotype 1 pneumonia in patient receiving adalimumab.](#)

[Wuerz TC, Mooney O, Keynan Y.](#)

[Emerg Infect Dis. 2012 Nov;18\(11\):1872-4. doi: 10.3201/eid1811.111505.](#)

[PMID:](#)

[23092579 Ota_kotona](#)

[\[PubMed - indexed for MEDLINE\]](#)

[Free PMC Article](#)

[Related citations](#)

Vuolteenaho K, Moilanen T, Hamalainen M,
Moilanen E. Effects of
TNFalpha-antagonists on nitric oxide production
in human cartilage.
Osteoarthritis Cartilage 2002;10:327–32.

Otettu 18.6.18

[Population pharmacokinetics of golimumab, an anti-tumor necrosis
factor-alpha human monoclonal antibody, in patients with psoriatic arthritis.](#)

Xu Z, Vu T, Lee H, Hu C, Ling J, Yan H, Baker D, Beutler A, Pendley C,
Wagner C, Davis HM, Zhou H.

J Clin Pharmacol. 2009 Sep;49(9):1056-70. Epub 2009 Jul 17.

Otettu 18.6.18

PMID:

19617465

[PubMed - indexed for MEDLINE]

[Related citations](#)

[Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity.](#)

Xu ZH, Lee H, Vu T, Hu C, Yan H, Baker D, Hsu B, Pendley C, Wagner C, Davis HM, Zhou H.

Int J Clin Pharmacol Ther. 2010 Sep;48(9):596-607. ei ole M

PMID:

20860913

[PubMed - indexed for MEDLINE]

[Related citations](#)

342.

Spontaneous resolution of lupus nephritis following withdrawal of etanercept.

Yahya TM, Dhanyamraju S, Harrington TM,
Prichard JW.

Ann Clin Lab Sci. 2013 Fall;43(4):447-9.

PMID:

24247804

[PubMed - indexed for MEDLINE] ei ole M

Related citations

327.

Postoperative eyelid infection in a patient taking etanercept.

Yakopson VS, Flanagan JC.

Orbit. 2011 Dec;30(6):303-4.

PMID:

OTA myöhemmin

22132849

[PubMed - indexed for MEDLINE]

Related citations

Yamada T, Nakajima A, Inoue E et al

Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan.

Ann Rheum Dis 2006; 65: 1661-3 [Kokotekstinä](#)

273.

[Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial.](#)

Yamanaka H, Ishiguro N, Takeuchi T, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Kupper H, Arora V, Tanaka Y.

Rheumatology (Oxford). 2014 May;53(5):904-13. doi: 10.1093/rheumatology/ket465. Epub 2014 Jan 17.

PMID:

24441150

[PubMed - indexed for MEDLINE] Ota kotona

[Free PMC Article](#)

[Related citations](#)

Yamauchi PS,
Turner L,
Lowe NJ,
Gindi V,
Jackson MJ

. Treatment of recurrent Sweet's syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 2006;54:S122–6. Otettu M 12.11.09 Ei auennut 9.9.12

[CrossRefMedline](#)

[A Case of Disseminated Sporotrichosis Treated with Prednisolone, Immunosuppressants, and Tocilizumab under the Diagnosis of Rheumatoid Arthritis.](#)

Yamaguchi T, Ito S, Takano Y, Umeda N, Goto M, Horikoshi M, Hayashi T, Goto D, Matsumoto I, Sumida T.

Intern Med. 2012;51(15):2035-9. Epub 2012 Aug 1.

PMID:

22864133 OTA kotona

[PubMed - in process]

Free Article

[Related citations](#)

Acquired hemophilia A and fulminant diabetes mellitus possibly caused by adalimumab in a patient with psoriatic arthritis.

Yamaguchi T, Itoh M, Umezawa Y, Asahina A, Hanabusa H, Nakagawa H.

J Dermatol. 2017 Mar;44(3):e3-e4. doi: 10.1111/1346-8138.13468. Epub 2016 May 21. No abstract available.

PMID:

27206322 Otettu 19.6.18

[Similar articles](#)

Yamamoto M, Takahashi H, Wakasugi H, Sukawa Y, Saito M,

Suzuki C, et al. Leukoencephalopathy during administration of

etanercept for refractory rheumatoid arthritis.

Mod Rheumatol

2007;17:72-4. ei ole M

Yamanaka H, Tanaka Y, Sekiguchi N et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis

management group in Japan (RECONFIRM). Mod Rheumatol 2007;17:28-32
Otettu M 12.11.09 Ei oteta

[Adalimumab for the prevention of recurrence after surgery for Crohn's disease.](#)

Yamamoto T.

Eur J Gastroenterol Hepatol. 2012 Jul;24(7):863; author reply 863-4. No abstract available.

Otettu 19.6.18

PMID:

22668832

[PubMed - in process]

[Related citations](#)

Yamauchi P. Adalimumab in the management of hidradenitis suppurativa. J Am Acad Dermatol 2007;56:AB41. Ei löydy

[Hidradenitis suppurativa managed with adalimumab.](#)

Yamauchi PS, Mau N.

J Drugs Dermatol. 2009 Feb;8(2):181-3. ei ole M

PMID: 19213236 [PubMed - indexed for MEDLINE][Related citations](#)

[Adalimumab treats psoriasis in patients previously treated with etanercept: a case series.](#)

Yamauchi PS, Mau N.

J Am Acad Dermatol. 2009 Jul;61(1):158-60. No abstract available.

PMID: 19539861 [PubMed - in process] Otettu M 12.11.09 Ei aukea

[Related Articles](#)

Yan TD, Kavuru MS, Yen-Lieberman B, Brzezinski A,

Gordon SM. Immune function evaluation (ImmunoKnow Assay) in a patient treated with infliximab who developed miliary histoplasmosis. Infect Dis Clin Pract 2005;13:315–17. Otettu M
12.11.09 **Ei oteta**

[Levels of Drug and Anti-drug Antibodies are Associated with Outcome of Interventions after Loss of Response to Infliximab or Adalimumab.](#)

Yanai H, Lichtenstein L, Assa A, Mazor Y, Weiss B, Levine A, Ron Y, Kopylov U, Bujanover Y, Rosenbach Y, Ungar B, Eliakim R, Chowers Y, Shamir R, Fraser G, Dotan I, Ben-Horin S.

Clin Gastroenterol Hepatol. 2014 Jul 24. pii: S1542-3565(14)01074-X. doi: 10.1016/j.cgh.2014.07.029. [Epub ahead of print]

PMID:

25066837

[PubMed - as supplied by publisher] ei ole M

[Related citations](#)

[Etanercept as a rescue agent in patient with adult onset Still's disease complicated with congestive heart failure.](#)

Yang DH, Chang DM, Lai JH, Kuo SY, Ho TY, Lin KM, Chen CH.

Rheumatol Int. 2008 Nov;29(1):95-8. Epub 2008 May 24. **OK**

PMID: 18500457 [PubMed - indexed for MEDLINE] Otettu m 12.11.09

[Related Articles](#)

162.

[Golimumab for the treatment of psoriatic arthritis.](#)

Yang H, Epstein D, Bojke L, Craig D, Light K, Bruce I, Sculpher M, Woolacott N.

Health Technol Assess. 2011 May;15 Suppl 1:87-95. Review.

ei oteta

PMID:

21609657

[PubMed - indexed for MEDLINE]

[Related citations](#)

249.

[Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.](#)

Yang H, Craig D, Epstein D, Bojke L, Light K, Bruce IN, Sculpher M, Woolacott N.

Pharmacoconomics. 2012 Apr;30(4):257-70. doi: 10.2165/11595920-00000000-00000. Review.

PMID: ei oteta

22283690

[PubMed - indexed for MEDLINE]

[Related citations](#)

[Etanercept Attenuates Myocardial Ischemia/Reperfusion Injury by Decreasing Inflammation and Oxidative Stress.](#)

Yang M, Chen J, Zhao J, Meng M.

PLoS One. 2014 Sep 26;9(9):e108024. doi: 10.1371/journal.pone.0108024.

eCollection 2014.

PMID:

25260027

[PubMed - as supplied by publisher] ei oteta

[Related citations](#)

129.

[Safety and efficacy of etanercept-methotrexate combination therapy in patients with rhupus: an observational study of non-glucocorticoid treatment for rheumatic diseases.](#)

Yang BB, Xiao H, Li XJ, Zheng M.

Discov Med. 2018 Jan;25(135):14-20.

PMID:

29466690 Ota kotona

[Free Article](#)

[Similar articles](#)

Yanik, G. A., Ho, V. T., Levine, J. E., White, E. S., Braun, T., Antin, J. H., Whitfield, J., Custer, J., Jones, D., Ferrara, J. L. M., Cooke, K. R. (2008). The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. *Blood* 112: 3073-3081 Otettu M 12.11.09

- [\[Abstract\]](#) [\[Full Text\]](#)

-

132.

[Metastatic bone lesion due to methotrexate and etanercept 24 years after breast cancer treatment.](#)

Yano S.

BMJ Case Rep. 2014 Apr 12;2014. pii: bcr2013202615. doi:
10.1136/bcr-2013-202615.

PMID:

24729113

[PubMed - in process] Otettu 19.6.18

[Related citations](#)

[Bilateral facial nerve palsies secondary to chronic inflammatory demyelinating polyneuropathy following adalimumab treatment.](#)

Yao A, Chan H, Macdonell RAL, Shuey N, Khong JJ.

Clin Neurol Neurosurg. 2018 Jan;164:64-66. doi: 10.1016/j.clineuro.2017.11.001. Epub 2017 Nov 22.

PMID:

29179036 Otettu 19.6.18

[Similar articles](#)

[Subacute thyroiditis in a patient with juvenile idiopathic arthritis undergoing etanercept treatment: a case report and review of the literature.](#)

Yasuji I.

Mod Rheumatol. 2012 Jun 6. [Epub ahead of print]

PMID: Otettu 19.6.18

22669598

[PubMed - as supplied by publisher]

[Related citations](#)

502.

[Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis.](#)

Yates M, Loke YK, Watts RA, MacGregor AJ.

Clin Rheumatol. 2014 Feb;33(2):227-36. doi: 10.1007/s10067-013-2384-2. Epub 2013 Sep 12.

PMID:

24026674

[PubMed - in process] Otettu 19.6.18

[Related citations](#)

684.

[Is Etanercept 25 mg Once Weekly as Effective as 50 mg at Maintaining Response in Patients with Ankylosing Spondylitis? A Randomized Control Trial.](#)

Yates M, Hamilton LE, Elender F, Dean L, Doll H, MacGregor AJ, Thomas J, Gaffney K.

J Rheumatol. 2015 Jul;42(7):1177-85. doi: 10.3899/jrheum.141335.

PMID:

26034151 Otettu 19.6.18

[Similar articles](#)

B. Yazdani-Biuki, T. Mueller, H.-P. Brezinschek, J. Hermann, W. Graninger, and T. C. Wascher

Relapse of Diabetes After Interruption of Chronic Administration of Anti-Tumor Necrosis Factor- α Antibody Infliximab: A case observation

Diabetes Care, July 1, 2006; 29(7): 1712 - 1713. Otettu M 12.11.09

[\[Full Text\]](#) [\[PDF\]](#) [Ei oteta](#)

YAZDANI-BIUKI B, STADLMAIER E, MULABECIROVIC A

Blockade of tumour necrosis factor alpha significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis.

[Kokotekstinä](#) (PDF)

Ann. Rheum. Dis. 2005; 64: 1224–1226.

Ref. tarkistetu 12.11.09

Yazici Y, Erkan D, Lockshin MD. A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis. Clin Exp Rheumatol 2000;18:732–4. [\[Medline\]](#)

[Kokotekstinä](#) (PDF) [Ei oteta](#)

POimittu koneelle 1.10.09

Ref. tarkistettu 11.11.09

Yazici Y, Erkan D, Kulman I, Belostocki K, Harrison MJ.

Decreased flares of rheumatoid arthritis during the first year of etanercept treatment: further evidence of clinical effectiveness in the “real world”. Ann Rheum Dis 2002;61:638-40. Otettu m 12.11.09

YAZICI Y, YAZICI H

Trial of etanercept and methotrexate with radiographic and patient outcomes two-year clinical and radiographic results: Comment on the article by van der Heijde et al.

Arthritis Rheum 2006; 54:3061-2. [Kokotekstinä](#) (PDF)

Poimittu koneelle 11.11.09

Yazici Y, Yazici H.

[Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis.](#)

Clin Exp Rheumatol. 2008 May-Jun;26(3):449-52.

[Kokotekstinä](#) (PDF)

Poimittu koneelle 1.10.09

Ref. tarkistettu 11.11.09

[Related Articles](#)

Yazici Y, Krasnokutsky S, Barnes JP et al

[Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis.](#)

J Rheumatol. 2009 May;36(5):907-13 [Kokotekstinä](#) (PDF)

Poimittu koneelle 11.11.2009

[Related Articles](#)

Yazici Y, Erkan D, van Vollenhoven RF

Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed? * Author's reply

Ann Rheum Dis 2004; 63: 607 - 8. [Kokotekstinä](#) OK*

Y Yazici and H Yazici

A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor {alpha} inhibitors

Ann Rheum Dis, January 1, 2007; 66(1): 124 - 127. Otettu M 12.11.09

[\[Abstract\]](#) [\[Full Text\]](#) [\[PDF\]](#)

Yazici Y, Adler MN, Yazici H

Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations

Rheumatology, July 1, 2008; 47(7): 1054 - 1057. [Kokotekstinä](#) (PDF)

Ref. tarkistettu 12.11.09 [Ei oteta](#)

[\[Abstract\]](#) [\[Full Text\]](#) [\[PDF\]](#)

Yee AM, Pochapin MB.

Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy.

Ann Intern Med 2001;135:27–31. [Ei oteta](#)

[\[Abstract/Free Full Text\]](#)

Yee CS, Filer A, Pace A et al

The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study. Rheumatology 2003;42: 856-859 [Kokotekstinä](#) (PDF)

Poimittu koneelle 11.11.09

[\[Abstract\]](#) [\[Full Text\]](#)

Yelin E, Trupin L, Katz P et al

Association between etanercept use and employment outcomes among patients with rheumatoid arthritis.

Arthritis Rheum 2003;48:3046–54. [Kokotekstinä](#) (PDF) [Ei oteta](#)

Poimittu koneelle 11.11.09

Yentzer BA, Yelverton CB, Simpson GL et al

[Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis.](#)

Dermatol Online J. 2009 Apr 15;15(4):1. [Kokotekstinä](#) Ei oteta

[Related Articles](#) [Free article in PMC](#) | [at journal site](#)

[Select item 2344178264.](#)

[Treatment of multicentric reticulohistiocytosis with adalimumab, minocycline, methotrexate.](#)

[Yeter KC, Arkfeld DG.](#)

[Int J Rheum Dis. 2013 Feb;16\(1\):105-6. doi:](#)

[10.1111/j.1756-185X.2012.01762.x. Epub 2012 Jun 7. No abstract available.](#)

[PMID:](#)

[23441782](#) Otettu 19.6.18

[\[PubMed - in process\]](#)

[Related citations](#)

W. W. Yew and C. C. Leung

Update in Tuberculosis 2006

Am. J. Respir. Crit. Care Med., March 15, 2007; 175(6): 541 - 546. Otettu M 12.11.09

[\[Full Text\]](#) [\[PDF\]](#)

W. W. Yew and C. C. Leung

Update in Tuberculosis 2007

Am. J. Respir. Crit. Care Med., March 1, 2008; 177(5): 479 - 485. Otettu M 12.11.09

[\[Full Text\]](#) [\[PDF\]](#)

[The effect of etanercept on a case of amyloidosis secondary to ankylosing spondylitis: results of 2-year follow-up.](#)

Yilmaz H, Kocabas H, Erkin G.

Acta Reumatol Port. 2013 Oct-Dec;38(4):299-301.

PMID:

24435036

[PubMed - in process] Katso

[Free Article](#)

[Related citations](#)

Select item 24431398273.

Yim K, Nazeer SH, Kiska D, Rose FB, Brown D, Cynamon MH. Recurrent *Mycobacterium xenopi* infection in a patient

with rheumatoid arthritis receiving etanercept.
Scand J Infect
Dis 2004;36:150-4.

Yim DS, Zhou H, Buckwalter M et al

Population Pharmacokinetic Analysis and Simulation of the Time-Concentration Profile of Etanercept in Pediatric Patients With Juvenile Rheumatoid Arthritis.

J Clin Pharmacol 2005;45: 246-56 Otettu M 12.11.09 **Ei oteta**

[\[Abstract\]](#) [\[Full Text\]](#)

[Myelitis and optic neuritis induced by a long course of etanercept in a patient with rheumatoid arthritis.](#)

Yokoyama W, Takada K, Miyasaka N, Kohsaka H.

BMJ Case Rep. 2014 Aug 1;2014. pii: bcr2014205779. doi: 10.1136/bcr-2014-205779.

PMID:

25085953

[PubMed - as supplied by publisher] Otettu 19.6.18

[Related citations](#)

Youdim A, Vasiliauskas EA, Targan SR et al
A pilot study of adalimumab in infliximab allergic patients.
Inflammatory Bowel Diseases 2004; 10: 333–338. Otettu M 12.11.09

Yousem SA, Dacic S.
Pulmonary lymphohistiocytic reactions temporarily related to etanercept therapy.
Mod Pathol 2005; 18:651-5. Otettu M 12.11.09

Yocum D.
Effective use of TNF antagonists. Ei oteta
Arthritis Res Ther 2004;6:S24–30. [Kokotekstinä](#) (PDF)
Poimittu koneelle 12.11.09
Ref. tarkistettu 12.11.09

232.

[Incidences of serious infections and tuberculosis among patients receiving anti-tumor necrosis factor-a therapy.](#)

Yoo IK, Choung RS, Hyun JJ, Kim SY, Jung SW, Koo JS, Lee SW, Choi JH, Kim H, Lee HS, Keum B, Kim ES, Jeen YT.

Yonsei Med J. 2014 Mar;55(2):442-8. doi: 10.3349/ymj.2014.55.2.442.

PMID:

24532516

[PubMed - in process] Ota kotona

[Free PMC Article](#)

[Related citations](#)

[Young JD, McGwire BS, Callegari PE](#)

Infliximab and Reactivation of Cerebral Toxoplasmosis.

[NEJM](#) 2005; 353: 1530-31 OK

[Eosinophilic colitis under etanercept.](#)

Yozgat A, Colak A, Koseoglu HT, Altinbas A.

Acta Gastroenterol Belg. 2015 Dec;78(4):439-40.

PMID:

26712058 ei oteta

[Similar articles](#)

Yucel AE, Kart-Koseoglu H, Akova YA et al
Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Behcet's disease
Rheumatology 2004; 43: 394 - 6. [Kokotekstinä](#) [OK*](#)

8.

[Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.](#)

Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, Saag KG, Beukelman T, Winthrop K, Baddley JW, Curtis JR.

Ann Rheum Dis. 2014 Mar 7. doi: 10.1136/annrheumdis-2013-204011. [Epub ahead of print]

PMID:

24608404

[PubMed - as supplied by publisher] Otettu 19.6.18

[Related citations](#)

Select item 24608401199.

[Risks of Herpes Zoster in Patients with Rheumatoid Arthritis According to Biologic Disease Modifying Therapy.](#)

Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, Saag KG, Beukelman T, Winthrop K, Baddley JW, Curtis JR.

Arthritis Care Res (Hoboken). 2014 Sep 8. doi: 10.1002/acr.22470. [Epub ahead of print]

PMID:

25201241

[PubMed - as supplied by publisher] ei ole M

[Related citations](#)

Zachariae C, Mørk NJ, Reunala T et al

[The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy.](#)

Acta Derm Venereol. 2008;88(5):495-501. Otettu M 12.11.09

[Related Articles](#)

[Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe.](#)

Zanger P, Kötter I, Kremsner PG, Gabrysch S.

Clin Microbiol Infect. 2012 Jul;18(7):670-6. doi: 10.1111/j.1469-0691.2011.03674.x. Epub 2011 Oct 10.

PMID: Otettu 19.6.18

21985586

[PubMed - in process]

[Related citations](#)

Zangrilli A, Esposito M, Mio G et al

Longterm efficacy of etanercept in hidradenitis suppurativa.

J Eur Acad Dermatol Venereol 2008;22:1260-2. Otettu M 12.11.09

Zamarron C, Maceiras F, Mera A, Gomez-Reino JJ.

Effect of the first infliximab infusion on sleep and alertness in patients with active rheumatoid arthritis.

Ann Rheum Dis 2004;63:88-90. [Kokotekstinä](#) (PDF)

Ref. tarkistettu 12.11.09 [Ei oteta](#)

POimittu koneelle

[**Adalimumab** regulates intracellular TNFalpha production in patients with rheumatoid arthritis.](#)

Zamora-Atenza C, Diaz-Torne C, Geli C, Diaz-Lopez C, Ortiz MA, Moya P,

Castellví I, Nieto JC, Cantó E, Casademont J, Juarez C, Llobet JM, Vidal S.

Arthritis Res Ther. 2014 Jul 18;16(4):R153. [Epub ahead of print]

PMID:

25037855

[PubMed - as supplied by publisher] Otettu 19.6.18

[Related citations](#)

Etanercept in the treatment of psoriasis and psoriatic arthritis with concomitant hepatitis C virus infection: clinical and virological study in three patients.

Zanni M, Missale G, Santilli D, Di Nuzzo S.

Eur J Dermatol. 2011 Jul-Aug;21(4):564-7. ei ole M

PMID:

21543290

[PubMed - indexed for MEDLINE]

[Related citations](#)

Zavos C, Kountouras J, Zavos N, Chatzopoulos D. Inhibition of

tumour necrosis factor-alpha in patients with chronic hepatitis C infection. Clin Rheumatol 2007;26:283.

Thrombotic thrombocytopenic purpura associated with **adalimumab** (Humira) treatment in Crohn disease.

Zbaras B, Sam LN, Grimm MC.

Intern Med J. 2013 Feb;43(2):216-7. doi: 10.1111/imj.12055. No abstract available.

PMID:

23402489 Otettu 19.6.18

[PubMed - in process]

Related citations

Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in

the spondyloarthropathies: a systematic literature review. Ann Rheum Dis. 2008;67(7):955-9. Otettu m 12.11.09 **Ei oteta**

Zein NN

Etanercept as an adjuvant to interferon and ribavirin in treatment-naïve patients with chronic hepatitis C virus infection: a phase 2 randomized double blind placebo-controlled study. Otettu M 12.11.09
J Hepatol 2005; **42**:315–2. [[CrossRef](#)] [[ISI](#)] [[Medline](#)]

[216.](#)

[Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.](#)

[Zelinkova Z, van der Ent C, Bruin KF, van Baalen O, Vermeulen HG, Smalbraak HJ, Ouwendijk RJ, Hoek AC, van der Werf SD, Kuipers EJ, van der Woude CJ; Dutch Delta IBD Group.](#)

[Clin Gastroenterol Hepatol. 2013 Mar;11\(3\):318-21. doi: 10.1016/j.cgh.2012.10.024. Epub 2012 Oct 25.](#)

[PMID:](#)

[23103819 ei ole M](#)

[\[PubMed - in process\]](#)

[Related citations](#)

[Zeissig S, Bojarski C, Buergel N, et al.](#)

Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor {alpha} antibody treatment

[Gut](#) 2004; **53**: 1295 - 1302. [Kokotekstinä](#) [OK](#)

[Drug-induced lupus associated with](#)

infliximab and adalimumab in an adolescent with Crohn disease.

Zella GC, Weinblatt ME, Winter HS.

J Pediatr Gastroenterol Nutr. 2009

Sep;49(3):355-8. No abstract available.

Otettu 19.6.18

MPMID: 19516196 [PubMed - indexed for MEDLINE]Related citations

Zellweger JP, Zellweger A, Ansermet S et al

Contact tracing using a new T-cell-based test: better correlation with tuberculosis exposure than the tuberculin skin test.

Int J Tuberc Lung Dis. 2005;9:1242-7. Ei ole M netissä

[PMID: 16333932].[Medline]

Zeltser R, Valle L, Tanck C, ym. Clinical, Histological, and Immunophenotypic Characteristics of Injection Site Reactions Associated With Etanercept: A Recombinant Tumor Necrosis Factor [alpha] Receptor: Fc Fusion Protein. Arch Dermatol 2001;137: 893-9. Kokotekstinä OK*

Zhang Z, Correa H, Bégué RE: Tuberculosis and treatment with infliximab [letter]. N Engl J Med 2002, 346:624. *

Zhang X, Kohli M, Zhou Q, et al. Short- and Long-Term Effects of IL-1 and TNF Antagonists on Periodontal Wound Healing. J Immunol 2004;173: 3514-23

Kokotekstinä

*

ZHANG Z, CORREA H, BEGUE RE: Tuberculosis and treatment with infliximab.

N Engl J Med 2002; 346:623-6. Otettu M 12.11.09

Treatment of necrobiosis lipoidica with etanercept and adalimumab.

Zhang KS, Quan LT, Hsu S.

Dermatol Online J. 2009 Dec 15;15(12):12. No abstract available. PMID: 20040262 [PubMed - indexed for MEDLINE]

Ei oteta

Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis.

Zhang J, Xie F, Yun H, Chen L, Muntner P, Levitan EB, Safford MM, Kent ST, Osterman MT, Lewis JD, Saag K, Singh JA, Curtis JR.

Ann Rheum Dis. 2016 Oct;75(10):1813-8. doi: 10.1136/annrheumdis-2015-207870. Epub 2016 Jan 20.

PMID:

26792814 Otettu 19.6.18

Similar articles

Etanercept in the treatment of refractory SAPHO syndrome.

Zhang L, Gao Z.

Am J Clin Exp Immunol. 2016 Nov 30;5(4):62-66. eCollection 2016.

PMID:

28078192 Ota kotona

[**Free PMC Article**](#)

[Similar articles](#)

[**Etanercept for the treatment of rheumatoid arthritis.**](#)

Zhao S, Mysler E, Moots RJ.

Immunotherapy. 2018 Mar 1;10(6):433-445. doi: 10.2217/imt-2017-0155. Epub 2018 Feb 27.

PMID:

29482402 ei ole M

[Similar articles](#)

Zhou H, Parks V, Patat A et al

Absence of a Clinically Relevant Interaction Between Etanercept and Digoxin.

J Clin Pharmacol 2004; 44: 1244-51 Otettu M 12.11.09 **Ei oteta**

[\[Abstract\]](#) [\[Full Text\]](#)

Zhou H

Clinical Pharmacokinetics of Etanercept: A Fully Humanized Soluble Recombinant Tumor Necrosis Factor Receptor Fusion Protein.

J Clin Pharmacol 2005; 45: 490-7 Otettu M 12.11.09

- [\[Abstract\]](#) [\[Full Text\]](#)

[Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.](#)

Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, Pendley C, Jiao Q, Shankar G, Marciniak SJ, Cohen SB, Rahman MU, Baker D, Mascelli MA, Davis HM, Everitt DE.

J Clin Pharmacol. 2007 Mar;47(3):383-96.

Otettu 19.6.18

PMID:

17322150

[PubMed - indexed for MEDLINE]

[Related citations](#)

[Integrated Population Pharmacokinetics of Etanercept in Healthy Subjects and Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.](#)

Zhou SY, Shu C, Korth-Bradley J, Raible DG, Palmisano M, Wadjula J, Fatenejad S, Bjornsson T.

J Clin Pharmacol. 2010 Sep 17. [Epub ahead of print]

Otettu 19.6.18

PMID:

20852002

[PubMed - as supplied by publisher]

[Related citations](#)

886.

[Cat scratch disease during infliximab therapy: a case report and literature review.](#)

Zhou Y, Yin G, Tan C, Liu Y.

Rheumatol Int. 2015 May;35(5):911-3. doi: 10.1007/s00296-014-3204-y. Review.

PMID:

25547623 Otettu 19.6.18

[Similar articles](#)

[Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.](#)

Zhuang Y, Xu Z, Frederick B, de Vries DE, Ford JA, Keen M, Doyle MK, Petty KJ, Davis HM, Zhou H. Clin Ther. 2012 Jan;34(1):77-90. Epub 2011 Dec 14.

Otettu 19.6.18

PMID:

22169051

[PubMed - indexed for MEDLINE]

[Related citations](#)

Ziakas P D, Giannouli S, Tzioufas A G et al
Lymphoma development in a patient receiving anti-TNF therapy.
Haematologica 2003;88:ECR25. **OK***
[Kokotekstinä](#) (PDF)

TNF-alpha and its inhibitors in cancer.

Zidi I, Mestiri S, Bartegi A, Amor NB.
Med Oncol. 2010 Jun;27(2):185-98. Epub 2009 Mar 11. Review.
ei oteta
PMID:

19277912

[PubMed - indexed for MEDLINE]

[Related citations](#)

Golimumab therapy of rheumatoid arthritis: an overview.

Zidi I, Bouaziz A, Mnif W, Bartegi A, Al-Hizab FA, Amor NB.
Scand J Immunol. 2010 Aug;72(2):75-85. Review.
Otettu 19.6.18
PMID:

20618765

[PubMed - indexed for MEDLINE]

[Related citations](#)

Golimumab and malignancies: true or false association?

Zidi I, Bouaziz A, Mnif W, Bartegi A, Ben Amor N.
Med Oncol. 2010 Apr 7. [Epub ahead of print] ei ole M
PMID:

20373059

[PubMed - as supplied by publisher]

[Related citations](#)

[Dermatologic adverse events: golimumab, friend or foe?](#)

Zidi I, Bartegi A, Ben AN.

Pharmazie. 2011 Jan;66(1):5-10. Review.

Otettu 19.6.18

PMID:

21391428

[PubMed - indexed for MEDLINE]

[Related citations](#)

Ziegelstein RC

Prescribing Antitumor Necrosis Factor Drugs to Patients With Heart Failure

Archives of Internal Medicine 2005; 165: 118 - 9. Otettu M 12.11.09 **Ei oteta**

[\[Full Text\]](#) [\[PDF\]](#)

Zink A, Listing J, Kary S et al

Treatment continuation in patients receiving biological agents or conventional DMARD therapy

Ann Rheum Dis 2005; 64: 1274 - 9.

Sitaatit tarkistettu 10.2.08 [Kokotekstinä](#) [Ei oteta](#)

Ziołkowska M, Kurowska M, Radzikowska A,

High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.

Arthritis Rheum 2002;46:1744–53. [Kokotekstinä](#) (PDF)

Poimittu koneelle 11.11.09

Ref. tarkistettu 11.11.09

Ziołkowska M, Maslinski W.

Laboratory changes on anti-tumor necrosis factor treatment in rheumatoid arthritis.

Curr Opin Rheumatol 2003; 15: 267–273 Otettu M 12.11.09 [Ei oteta](#)

[\[CrossRef\]](#)[\[ISI\]](#)[\[Medline\]](#)

489.

[Squamous cell carcinoma of the lip associated with adalimumab therapy for ankylosing spondylitis: a case report and review of TNF- \$\alpha\$ inhibitors and cutaneous carcinoma risk.](#)

Zitelli KB, Zedek D, Ranganathan P, Amerson EH.

Cutis. 2013 Jul;92(1):35-9. Review.

PMID:

23961524

[PubMed - indexed for MEDLINE] ei ole M

[Related citations](#)

74.

[Effects of TNF inhibitor on innate inflammatory and Th17 cytokines in stimulated whole blood from rheumatoid arthritis patients.](#)

Zivojinovic S, Pejnovic N, Sefik-Bukilica M, Kovacevic L, Soldatovic I, Bugarski D, Mojsilovic S, Damjanov N.

Inflammopharmacology. 2012 Jun 24. [Epub ahead of print]

PMID: [Otettu 19.6.18](#)

22733231

[PubMed - as supplied by publisher]

[Related citations](#)

326.

[Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.](#)

Zivojinovic SM, Pejnovic NN, Sefik-Bukilica MN, Kovacevic LV, Soldatovic II, Damjanov NS. J Rheumatol. 2012 Jan;39(1):18-21. Epub 2011 Dec 1.

PMID:

22133625

[PubMed - indexed for MEDLINE] [Otettu 19.6.18](#)

[Related citations](#)

J. Zochling, J. Brandt, and J. Braun

The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis

Rheumatology, December 1, 2005; 44(12): 1483 - 1491. [Ei oteta](#)

[\[Full Text\]](#) [\[PDF\]](#)

J Zochling, D van der Heijde, M Dougados, and J Braun

Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis

Ann Rheum Dis, April 1, 2006; 65(4): 423 - 432. [Ei oteta](#)

[\[Abstract\]](#) [\[Full Text\]](#) [\[PDF\]](#)

Zochling J, van der Heijde D, Burgos-Vargas R et al

ASAS/EULAR recommendations for the management of ankylosing spondylitis

Ann Rheum Dis 2006; 65: 442 - 52. [Kokotekstinä](#) [Ei oteta](#)

[Successful use of adalimumab for treating fistulizing Crohn's disease with pyoderma gangrenosum: Two birds with one stone.](#)

Zold E, Nagy A, Devenyi K, Zeher M, Barta Z.

World J Gastroenterol. 2009 May 14;15(18):2293-5. [Kokotekstinä](#) [Ei oteta](#)

[PubMed - indexed for MEDLINE][Free PMC Article](#)[Free text](#)[Related citations](#)

Zochling J, van der Heijde D, Dougados M et al

Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.

Ann Rheum Dis 2006; 65: 423-432 **Ei oteta**

Poimittu koneelle 11.11.09

- [\[Abstract\]](#) [\[Full Text\]](#)

Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.

Zorzi F, Zuzzi S, Onali S, Calabrese E, Condino G, Petruzzello C, Ascolani M, Pallone F, Biancone L.

Aliment Pharmacol Ther. 2012 Jun;35(12):1397-407. doi: 10.1111/j.1365-2036.2012.05100.x. Epub 2012 Apr 22. Otettu 19.6.18

PMID:

22519466

[PubMed - in process]

[Related citations](#)

Zou JX, Braun J, Sieper J. Immunological basis for the use of TNF-blocking agents in ankylosing spondylitis and immunological changes during treatment. Clin Exp Rheumatol 2002;20 (suppl 28) :34-7.

Poimittu koneelle 1.10.09

Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum 2003; 48: 780-90. [Links](#) [PubMed](#) | [CrossRef](#)

Kokotekstinä Ei oteta

[Zou J](#) , Rudwaleit M, Brandt J, et al.

Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept.

Ann Rheum Dis 2003; 62: 561-4. [Kokotekstinä](#) (PDF)

Ref. tarkistettu 11.11.09 **Ei oteta**

[Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.](#)

Zouboulis CC, Okun MM, Prens EP, Gniadecki R, Foley PA, Lynde C, Weisman J, Gu Y, Williams DA, Jemec GBE.

J Am Acad Dermatol. 2018 May 31. pii: S0190-9622(18)30836-3. doi: 10.1016/j.jaad.2018.05.040. [Epub ahead of print]

PMID:

29860040 Otettu 19.6.18

[Similar articles](#)

[Alopecia areata during treatment with adalimumab: therapy with an alternative TNF-alpha inhibitor is possible.](#)

Zschoche C, Bidier M, Hadaschik E.

J Dtsch Dermatol Ges. 2013 Jan 2. doi: 10.1111/ddg.12027. [Epub ahead of print] No abstract available.

PMID:

23279686 ei ole M

[PubMed - as supplied by publisher]

[Related citations](#)

J. ZWERINA, K. REDLICH, G. SCHETT, and J. S. SMOLEN

Pathogenesis of Rheumatoid Arthritis: Targeting Cytokies

Ann. N.Y. Acad. Sci., June 1, 2005; 1051(1): 716 - 729. [Ei oteta](#)

[\[Abstract\]](#) [\[Full Text\]](#) [\[PDF\]](#)

Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naïve rheumatoid arthritis patients.

Østergaard M, Emery P, Conaghan PG, Fleischmann R, Hsia EC, Xu W, Rahman MU.

Arthritis Rheum. 2011 Dec;63(12):3712-22. doi: 10.1002/art.30592. [Kokotekstinä](#)

PMID:

22127693 Otettu 19.6.18

[PubMed - indexed for MEDLINE]

[Related citations](#)